

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

**EP 1 407 774 A1**

(12)

## EUROPEAN PATENT APPLICATION

(43) Date of publication:

**14.04.2004 Bulletin 2004/16**

(51) Int Cl.<sup>7</sup>: **A61K 31/517**, C07D 239/95,  
C07D 401/12, C07D 403/04,  
A61P 3/06

(21) Application number: **02020255.2**

(22) Date of filing: **10.09.2002**

(84) Designated Contracting States:

**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR  
IE IT LI LU MC NL PT SE SK TR**

Designated Extension States:

**AL LT LV MK RO SI**

(71) Applicant: **LION bioscience AG**

**69123 Heidelberg (DE)**

(72) Inventors:

- **Deuschle, Ulrich**  
**69245 Bammental (DE)**
- **Loebbert, Ralph**  
**69115 Heidelberg (DE)**
- **Blume, Beatrix**  
**69221 Dossenheim (DE)**

• **Koegl, Manfred**

**69214 Eppenheim (DE)**

• **Kremoser, Claus**

**69121 Heidelberg (DE)**

• **Kober, Ingo**

**69251 Gaiberg (DE)**

• **Bauer, Ulrike**

**69207 Sandhausen (DE)**

• **Giegrich, Kristina**

**68623 Lampertheim (DE)**

(74) Representative: **Goddard, Heinz J., Dr. et al**

**FORRESTER & BOEHMERT**

**Pettenkoferstrasse 20-22**

**80336 München (DE)**

(54) **2-Amino-4-quinazolinones as LXR nuclear receptor binding compounds**

(57) The present invention relates to 2-amino-4-oxo-quinazolines which bind to the LXR receptors and act as agonists and antagonists of the LXR receptors. The invention further relates to the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and the production of medi-

caments using said compounds. In particular the compounds are useful in the treatment of hypercholesterolemia, obesity or other diseases associated with elevated lipoprotein (LDL) levels.

**EP 1 407 774 A1**

**Description**

**[0001]** The present invention relates to compounds according to the general formula (1), which bind to the LXR receptors and act as agonists and antagonists of the LXR receptors. The invention further relates to the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and the production of medicaments using said compounds.

**BACKGROUND OF THE INVENTION**

**[0002]** Multicellular organisms are dependent on advanced mechanisms of information transfer between cells and body compartments. The information that is transmitted can be highly complex and can result in the alteration of genetic programs involved in cellular differentiation, proliferation, or reproduction. The signals, or hormones, are often simple molecules, such as peptides, fatty acid, or cholesterol derivatives.

**[0003]** Many of these signals produce their effects by ultimately changing the transcription of specific genes. One well-studied group of proteins that mediate a cells response to a variety of signals is the family of transcription factors known as nuclear receptors, hereinafter referred to often as "NR". Members of this group include receptors for steroid hormones, vitamin D, ecdysone, cis and trans retinoic acid, thyroid hormone, bile acids, cholesterol-derivatives, fatty acids (and other peroxisomal proliferators), as well as so-called orphan receptors, proteins that are structurally similar to other members of this group, but for which no ligands are known (Escriva, H. et al., Ligand binding was acquired during evolution of nuclear receptors, PNAS, 94, 6803 - 6808, 1997). Orphan receptors may be indicative of unknown signaling pathways in the cell or may be nuclear receptors that function without ligand activation. The activation of transcription by some of these orphan receptors may occur in the absence of an exogenous ligand and/or through signal transduction pathways originating from the cell surface (Mangelsdorf, D. J. et al., The nuclear receptor superfamily: the second decade, Cell 83, 835-839, 1995).

**[0004]** In general, three functional domains have been defined in NRs. An amino terminal domain is believed to have some regulatory function. A DNA-binding domain hereinafter referred to as "DBD" usually comprises two zinc finger elements and recognizes a specific Hormone Responsive Element hereinafter referred to as "HRE" within the promoters of responsive genes. Specific amino acid residues in the "DBD" have been shown to confer DNA sequence binding specificity (Schena, M. & Yamamoto, K.R., Mammalian Glucocorticoid Receptor Derivatives Enhance Transcription in Yeast, Science, 241:965-967, 1988). A Ligand-binding-domain hereinafter referred to as "LBD" is at the carboxy-terminal region of known NRs. In the absence of hormone, the LBD of some but not all NRs appears to interfere with the interaction of the DBD with its HRE. Hormone binding seems to result in a conformational change in the NR and thus opens this interference (Brzozowski et al., Molecular basis of agonism and antagonism in the oestrogen receptor, Nature, 389, 753 - 758, 1997; Wagner et al., A structural role for hormone in the thyroid hormone receptor, Nature, 378, 690 - 697, 1995). A NR without the HBD constitutively activates transcription but at a low level.

**[0005]** Coactivators or transcriptional activators are proposed to bridge between sequence specific transcription factors and the basal transcription machinery and in addition to influence the chromatin structure of a target cell. Several proteins like SRC-1, ACTR, and Grip1 interact with NRs in a ligand enhanced manner (Heery et al., A signature motif in transcriptional coactivators mediates binding to nuclear receptors, Nature, 387, 733 - 736; Heinz et al., A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression, Nature 387, 43 - 47, 1997). Furthermore, the physical interaction with repressing receptor-interacting proteins or corepressors has been demonstrated (Xu et al., Coactivator and Corepressor complexes in nuclear receptor function, Curr Opin Genet Dev, 9 (2), 140 - 147, 1999).

**[0006]** Nuclear receptor modulators like steroid hormones affect the growth and function of specific cells by binding to intracellular receptors and forming nuclear receptor-ligand complexes. Nuclear receptor-hormone complexes then interact with a hormone response element (HRE) in the control region of specific genes and alter specific gene expression.

**[0007]** The term LXR (Liver X Receptor) includes all subtypes of this receptor. Specifically LXR includes LXRA (also known as LXRA $\alpha$ , RLD-1 and NR1H3) and LXR $\beta$  (also known as LXR $\beta$ , NER, NER1, UR, OR-1, R1P15 and NH1H2) and ligands of LXR should be understood to include ligands of LXRA or LXR $\beta$ . LXR is a prototypical type 2 nuclear receptor which activates genes upon binding to promoter region of target genes in a prototypical heterodimeric fashion with Retinoid X Receptor (hereinafter RXR, Forman et al., Cell, 81, 687-93, 1995). The relevant physiological ligands of LXR seem to be oxidized derivatives of cholesterol, including 22-hydroxycholesterol and 24,25(S)-epoxyc-cholesterol (Lehmann, et al., Biol. Chem. 272(6), 3137-40, 1997). The oxysterol ligands bound to LXR were found to regulate the expression of several genes that participate in cholesterol metabolism (Janowski, et al., Nature, 383, 728-31, 1996).

**[0008]** LXR is proposed to be a hepatic oxysterol sensor. Upon activation (e.g. binding of oxysterols) it influences the conversion of dietary cholesterol into bile acids by upregulating the transcription of key genes which are involved

in bile acid synthesis such as CYP7A1. Hence, activation of LXR in the liver could result in an increased synthesis of bile acids from cholesterol which could lead to decreased levels of hepatic cholesterol. This proposed LXR function in hepatic cholesterol metabolism was experimentally confirmed using knockout mice. Mice lacking the receptor LXRA lost their ability to respond normally to an increase in dietary cholesterol and did not induce transcription of the gene encoding CYP7A1. This resulted in accumulation of large quantities of cholesterol in the livers and impaired hepatic function. (Peet, et al., Cell, 93, 693-704, 1998).

[0009] Besides its important function in liver, LXR plays an important role in the regulation of cholesterol homeostasis in macrophages and intestinal mucosa cells where it upregulates cholesterol transporters from the ABC (=ATP binding cassette) family of membrane proteins (Repa, et al., J Biol Chem. 2002 May 24;277(21):18793-800). These transporters are believed to be crucially involved in the uptake of cholesterol from the diet since mutations in their genes leads to diseases such as sitosterolemia (Berge, et al., Science (2000);290(5497):1771-5.).

[0010] Other members of the ABC transporter family seem to be responsible for the efflux of cholesterol from loaded macrophages, a process which is thought to prevent the generation of atherosclerotic lesions. Stimulation of LXR by synthetic ligands might result in an increased cholesterol efflux from macrophages and a decreased deposition of atherosclerotic plaques (Venkateswaran, et al., PNAS (2000) 24;97(22):12097-102; Sparrow, et al., J Biol Chem (2002) 277(12):10021-7; Joseph, et al., PNAS (2002);99(11):7604-9).

[0011] However, in animal studies it was observed that activation of LXR in the liver by full agonists does not only increase bile acid synthesis but also stimulates the de novo synthesis of fatty acids and triglycerids through the up-regulation of key enzymes such as Fatty Acid Synthase (FAS) or Stearyl-CoA Desaturase (SCD-1). (Schultz, et al., Genes Dev (2000) 14(22):2831-8).

[0012] Therefore, an ideal synthetic LXR binding compound should have properties that retain the agonistic activity on hepatic bile acid formation and ABC-transporter -mediated decrease in cholesterol uptake from the diet and increased cholesterol efflux from macrophages. In parallel such a compound should lack the hyperlipidemic potential which is exerted through increased fatty acid and tricycleride synthesis.

[0013] To date few compounds have been described which bind the LXR receptor and thus show utility for treating diseases or conditions which are due to or influenced by said nuclear receptor (Collins, et al., J Med Chem. (2002) 45 (10):1963-6; Schultz, et al., Genes Dev (2000) 14(22):2831-8; Sparrow, et al., J Biol Chem (2002) 277(12):10021-7).

[0014] It was thus an object of the present invention to provide for compounds which by means of binding the LXR receptor act as agonist, antagonist or mixed agonist / antagonist of said receptor and thus show utility for treating diseases or conditions which are due to or influenced by said nuclear receptor.

[0015] It was further an object of the invention to provide for compounds that may be used for the manufacture of a medicament for the treatment of cholesterol associated conditions or diseases. In a preferred embodiment of the invention it was an object of the invention to provide for compounds that lower serum cholesterol and/or increase High Density lipoproteins (HDL) and/or decrease Low Density Lipoproteins (LDL). It was also an object of the invention to provide for compounds that may be used for the treatment of lipid disorders including hypercholesterolemia, atherosclerosis, Alzheimer's disease, skin disorders, obesity and diabetes.

## SUMMARY OF THE INVENTION

[0016] The present invention provides, *inter alia*, novel LXR nuclear receptor protein binding compounds according to the general formula (1) shown below. Said compounds are also binders of mammalian homologues of said receptor. Further the object of the invention was solved by providing for amongst the LXR nuclear receptor protein binding compounds according to the general formula (1) such compounds which act as agonists, antagonists or mixed agonists / antagonists of the human LXR receptor or a mammalian homologue thereof.


[0017] The invention provides for LXR agonists that may be used for the manufacture of a medicament for the treatment of cholesterol associated conditions or diseases. In a preferred embodiment of the invention it was an object of the invention to provide for compounds that lower serum cholesterol and/or increase High Density lipoproteins (HDL) and/or decrease Low Density Lipoproteins (LDL). It was also an object of the invention to provide for compounds that may be used for the treatment of lipid disorders including hypercholesterolemia, atherosclerosis, Alzheimer's disease, skin disorders, obesity and diabetes.

[0018] The foregoing merely summarizes certain aspects of the present invention and is not intended, nor should it be construed, to limit the invention in any manner. All patents and other publications recited herein are hereby incorporated by reference in their entirety.

## DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0019] The invention provides for a compound according to the following formula (1), or pharmaceutical acceptable salts or solvates thereof, hereinafter also referred to as the "compounds according to the invention" including particular

and preferred embodiments thereof, wherein



$R_1$ ,  $R_2$ ,  $R_3$  and/or  $R_4$ , is independently from each other selected from H, halogen, hydroxy, protected hydroxy, cyano, nitro,  $C_1$  to  $C_6$  alkyl,  $C_1$  to  $C_6$  substituted alkyl,  $C_1$  to  $C_7$  alkoxy,  $C_1$  to  $C_7$  substituted alkoxy,  $C_1$  to  $C_7$  acyl,  $C_1$  to  $C_7$  substituted acyl,  $C_1$  to  $C_7$  acyloxy, carboxy, protected carboxy, carboxymethyl, protected carboxymethyl, hydroxymethyl, protected hydroxymethyl, amino, protected amino, (monosubstituted)amino, protected (monosubstituted)amino, (disubstituted)amino, carboxamide, protected carboxamide, N-( $C_1$  to  $C_6$  alkyl)carboxamide, protected N-( $C_1$  to  $C_6$  alkyl)carboxamide, N, N-di( $C_1$  to  $C_6$  alkyl)carboxamide, trifluoromethyl, N-(( $C_1$  to  $C_6$  alkyl)sulfonyl)amino, N- (phenylsulfonyl) amino or phenyl, wherein the phenyl is substituted or unsubstituted, such that, for example, a biphenyl results.  $R_5$  is H,  $C_1$  to  $C_8$  alkyl,  $C_1$  to  $C_8$  substituted alkyl,  $C_7$  to  $C_{12}$  alkylphenyl or  $C_7$  to  $C_{12}$  substituted phenylalkyl,  $R_6$  is H,  $C_1$  to  $C_8$  alkyl,  $C_1$  to  $C_8$  substituted alkyl,  $C_7$  to  $C_{12}$  alkylphenyl or  $C_7$  to  $C_{12}$  substituted phenylalkyl,  $R_7$  is H,  $C_1$  to  $C_8$  alkyl,  $C_1$  to  $C_8$  substituted alkyl,  $C_7$  to  $C_{12}$  alkylphenyl or  $C_7$  to  $C_{12}$  substituted phenylalkyl,  $R_6$  and  $R_7$  may be taken together with nitrogen to form a heterocycle or substituted heterocycle or a heteroaryl or substituted heteroaryl ring.

**[0020]** The compounds of the invention can also exist as solvates and hydrates. Thus, these compounds may crystallize with, for example, waters of hydration, or one, a number of, or any fraction thereof of molecules of the mother liquor solvent. The solvates and hydrates of such compounds are included within the scope of this invention.

**[0021]** The symbol "H" denotes a hydrogen atom.

**[0022]** The term " $C_1$  to  $C_7$  acyl" encompasses groups such as formyl, acetyl, propionyl, butyryl, pentanoyl, pivaloyl, hexanoyl, heptanoyl, benzoyl and the like. Preferred acyl groups are acetyl and benzoyl.

**[0023]** The term " $C_1$  to  $C_7$  substituted acyl" denotes the acyl group substituted by one or more, and preferably one or two, halogen, hydroxy, protected hydroxy, oxo, protected oxo, cyclohexyl, naphthyl, amino, protected amino, (monosubstituted)amino, protected (monosubstituted)amino, (disubstituted)amino, guanidino, heterocyclic ring, substituted heterocyclic ring, imidazolyl, indolyl, pyrrolidinyl,  $C_1$  to  $C_7$  alkoxy,  $C_1$  to  $C_7$  acyl,  $C_1$  to  $C_7$  acyloxy, nitro,  $C_1$  to  $C_6$  alkyl ester, carboxy, protected carboxy, carbamoyl, carboxamide, protected carboxamide, N-( $C_1$  to  $C_6$  alkyl)carboxamide, protected N-( $C_1$  to  $C_6$  alkyl)carboxamide, N,N-di( $C_1$  to  $C_6$  alkyl)carboxamide, cyano, methylsulfonylamino, thiol,  $C_1$  to  $C_4$  alkylthio or  $C_1$  to  $C_4$  alkylsulfonyl groups. The substituted acyl groups may be substituted once or more, and preferably once or twice, with the same or with different substituents.

**[0024]** The term "substituted phenyl" specifies a phenyl group substituted with one or more, and preferably one or two, moieties chosen from the groups consisting of halogen, hydroxy, protected hydroxy, cyano, nitro,  $C_1$  to  $C_6$  alkyl,  $C_1$  to  $C_6$  substituted alkyl,  $C_1$  to  $C_7$  alkoxy,  $C_1$  to  $C_7$  substituted alkoxy,  $C_1$  to  $C_7$  acyl,  $C_1$  to  $C_7$  substituted acyl,  $C_1$  to  $C_7$  acyloxy, carboxy, protected carboxy, carboxymethyl, protected carboxymethyl, hydroxymethyl, protected hydroxymethyl, amino, protected amino, (monosubstituted)amino, protected (monosubstituted)amino, (disubstituted) amino, carboxamide, protected carboxamide, N-( $C_1$  to  $C_6$  alkyl)carboxamide, protected N-( $C_1$  to  $C_6$  alkyl)carboxamide, N, N-di( $C_1$  to  $C_6$  alkyl)carboxamide, trifluoromethyl, N-(( $C_1$  to  $C_6$  alkyl)sulfonyl)amino, N- (phenylsulfonyl)amino or phenyl, wherein the phenyl is substituted or unsubstituted, such that, for example, a biphenyl results.

**[0025]** Examples of the term "substituted phenyl" includes a mono- or di(halo)phenyl group such as 2, 3 or 4-chlorophenyl, 2,6-dichlorophenyl, 2,5-dichlorophenyl, 3,4-dichlorophenyl, 2, 3 or 4-bromophenyl, 3,4-dibromophenyl, 3-chloro-4-fluorophenyl, 2, 3 or 4-fluorophenyl and the like; a mono or di(hydroxy)phenyl group such as 2, 3 or 4-hydroxyphenyl, 2,4-dihydroxyphenyl, the protected-hydroxy derivatives thereof and the like; a nitrophenyl group such as 2, 3 or 4-nitrophenyl; a cyanophenyl group, for example, 2, 3 or 4-cyanophenyl; a mono- or di(alkyl)phenyl group such as 2, 3 or 4-methylphenyl, 2,4-dimethylphenyl, 2, 3 or 4-(iso-propyl)phenyl, 2, 3 or 4-ethylphenyl, 2, 3 or 4-(n-propyl) phenyl and the like; a mono or di(alkoxy)phenyl group, for example, 2,6-dimethoxyphenyl, 2, 3 or 4-methoxyphenyl, 2, 3 or 4-ethoxyphenyl, 2, 3 or 4-(isopropoxy)phenyl, 2, 3 or 4-(t-butoxy)phenyl, 3-ethoxy-4-methoxyphenyl and the like; 2, 3 or 4-trifluoromethylphenyl; a mono- or dicarboxyphenyl or (protected carboxy)phenyl group such as 2, 3 or 4-carboxyphenyl or 2,4-di(protected carboxy)phenyl; a mono- or di(hydroxymethyl)phenyl or (protected hydroxymethyl) phenyl such as 2, 3, or 4-(protected hydroxymethyl)phenyl or 3,4-di(hydroxymethyl)phenyl; a mono- or di(aminomethyl) phenyl or (protected aminomethyl)phenyl such as 2, 3 or 4-(aminomethyl)phenyl or 2,4-(protected aminomethyl)phenyl; or a mono- or di(N-(methylsulfonylamino))phenyl such as 2, 3 or 4-(N-(methylsulfonylamino))phenyl. Also, the term

"substituted phenyl" represents disubstituted phenyl groups wherein the substituents are different, for example, 3-methyl-4-hydroxyphenyl, 3-chloro-4-hydroxyphenyl, 2-methoxy-4-bromophenyl, 4-ethyl-2-hydroxyphenyl, 3-hydroxy-4-nitrophenyl, 2-hydroxy 4-chlorophenyl and the like.

**[0026]** The term "heteroaryl" means a heterocyclic aromatic derivative which is a five-membered or six-membered ring system having from 1 to 4 heteroatoms, such as oxygen, sulfur and/or nitrogen, in particular nitrogen, either alone or in conjunction with sulfur or oxygen ring atoms.

**[0027]** Examples of heteroaryls include pyridinyl, pyrimidinyl, and pyrazinyl, pyridazinyl, pyrrolo, furano, thiopheno, oxazolo, isoxazolo, phthalimido, thiazolo and the like.

**[0028]** The term "substituted heteroaryl" means the above-described heteroaryl is substituted with, for example, one or more, and preferably one or two, substituents which are the same or different which substituents can be halogen, hydroxy, protected hydroxy, cyano, nitro, C<sub>1</sub> to C<sub>6</sub> alkyl, C<sub>1</sub> to C<sub>7</sub> alkoxy, C<sub>1</sub> to C<sub>7</sub> substituted alkoxy, C<sub>1</sub> to C<sub>7</sub> acyl, C<sub>1</sub> to C<sub>7</sub> substituted acyl, C<sub>1</sub> to C<sub>7</sub> acyloxy, carboxy, protected carboxy, carboxymethyl, protected carboxymethyl, hydroxymethyl, protected hydroxymethyl, amino, protected amino, (monosubstituted)amino, protected (monosubstituted) amino, (disubstituted)amino, carboxamide, protected carboxamide, N-(C<sub>1</sub> to C<sub>6</sub> alkyl)carboxamide, protected N-(C<sub>1</sub> to C<sub>6</sub> alkyl)carboxamide, N, N-di(C<sub>1</sub> to C<sub>6</sub> alkyl)carboxamide, trifluoromethyl, N-((C<sub>1</sub> to C<sub>6</sub> alkyl)sulfonyl)amino or N-(phenylsulfonyl)amino groups.

**[0029]** The term "substituted naphthyl" specifies a naphthyl group substituted with one or more, and preferably one or two, moieties either on the same ring or on different rings chosen from the groups consisting of halogen, hydroxy, protected hydroxy, cyano, nitro, C<sub>1</sub> to C<sub>6</sub> alkyl, C<sub>1</sub> to C<sub>7</sub> alkoxy, C<sub>1</sub> to C<sub>7</sub> acyl, C<sub>1</sub> to C<sub>7</sub> acyloxy, carboxy, protected carboxy, carboxymethyl, protected carboxymethyl, hydroxymethyl, protected hydroxymethyl, amino, protected amino, (monosubstituted)amino, protected (monosubstituted)amino, (disubstituted)amino, carboxamide, protected carboxamide, N-(C<sub>1</sub> to C<sub>6</sub> alkyl)carboxamide, protected N-(C<sub>1</sub> to C<sub>6</sub> alkyl)carboxamide, N, N-di(C<sub>1</sub> to C<sub>6</sub> alkyl)carboxamide, trifluoromethyl, N-((C<sub>1</sub> to C<sub>6</sub> alkyl)sulfonyl)amino or N-(phenylsulfonyl)amino.

**[0030]** Examples of the term "substituted naphthyl" includes a mono or di(halo)naphthyl group such as 1, 2, 3, 4, 5, 6, 7 or 8-chloronaphthyl, 2, 6-dichloronaphthyl, 2, 5-dichloronaphthyl, 3, 4-dichloronaphthyl, 1, 2, 3, 4, 5, 6, 7 or 8-bromonaphthyl, 3, 4-dibromonaphthyl, 3-chloro-4-fluoronaphthyl, 1, 2, 3, 4, 5, 6, 7 or 8-fluoronaphthyl and the like; a mono or di(hydroxy)naphthyl group such as 1, 2, 3, 4, 5, 6, 7 or 8-hydroxynaphthyl, 2, 4-dihydroxynaphthyl, the protected-hydroxy derivatives thereof and the like; a nitronaphthyl group such as 3- or 4-nitronaphthyl; a cyanonaphthyl group, for example, 1, 2, 3, 4, 5, 6, 7 or 8-cyanonaphthyl; a mono- or di(alkyl)naphthyl group such as 2, 3, 4, 5, 6, 7 or 8-methylnaphthyl, 1, 2, 4-dimethylnaphthyl, 1, 2, 3, 4, 5, 6, 7 or 8-(isopropyl)naphthyl, 1, 2, 3, 4, 5, 6, 7 or 8-ethylnaphthyl, 1, 2, 3, 4, 5, 6, 7 or 8-(n-propyl)naphthyl and the like; a mono or di(alkoxy)naphthyl group, for example, 2, 6-dimethoxynaphthyl, 1, 2, 3, 4, 5, 6, 7 or 8-methoxynaphthyl, 1, 2, 3, 4, 5, 6, 7 or 8-ethoxynaphthyl, 1, 2, 3, 4, 5, 6, 7 or 8-(isopropoxy)naphthyl, 1, 2, 3, 4, 5, 6, 7 or 8-(t-butoxy)naphthyl, 3-ethoxy-4-methoxynaphthyl and the like; 1, 2, 3, 4, 5, 6, 7 or 8-trifluoromethylnaphthyl; a mono- or di-carboxynaphthyl or (protected carboxy)naphthyl group such as 1, 2, 3, 4, 5, 6, 7 or 8-carboxynaphthyl or 2, 4-di-(protected carboxy)naphthyl; a mono- or di(hydroxymethyl)naphthyl or (protected hydroxymethyl)naphthyl such as 1, 2, 3, 4, 5, 6, 7 or 8-(protected hydroxymethyl)naphthyl or 3, 4-di(hydroxymethyl)naphthyl; a mono- or di(amino)naphthyl or (protected amino)naphthyl such as 1, 2, 3, 4, 5, 6, 7 or 8-(amino)naphthyl or 2, 4-(protected amino)-naphthyl, a mono- or di(aminomethyl)naphthyl or (protected aminomethyl)naphthyl such as 2, 3, or 4-(aminomethyl)naphthyl or 2, 4-(protected aminomethyl)-naphthyl; or a mono- or di-(N-methylsulfonylamino) naphthyl such as 1, 2, 3, 4, 5, 6, 7 or 8-(N-methylsulfonylamino)naphthyl. Also, the term "substituted naphthyl" represents disubstituted naphthyl groups wherein the substituents are different, for example, 3-methyl-4-hydroxynaphth-1-yl, 3-chloro-4-hydroxynaphth-2-yl, 2-methoxy-4-bromonaphth-1-yl, 4-ethyl-2-hydroxynaphth-1-yl, 3-hydroxy-4-nitronaphth-2-yl, 2-hydroxy-4-chloronaphth-1-yl, 2-methoxy-7-bromonaphth-1-yl, 4-ethyl-5-hydroxynaphth-2-yl, 3-hydroxy-8-nitronaphth-2-yl, 2-hydroxy-5-chloronaphth-1-yl and the like.

**[0031]** The term "C<sub>1</sub> to C<sub>8</sub> alkyl" denotes such radicals as methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, amyl, tert-amyl, hexyl, n-heptyl, 2-heptyl, 3-heptyl, 4-heptyl, 2-methyl-hexyl, 2-methyl-2hexyl, 2-methyl-3-hexyl, n-octyl and the like.

**[0032]** Examples of the above substituted alkyl groups include the 2-oxo-prop-1-yl, 3-oxo-but-1-yl, cyanomethyl, nitromethyl, chloromethyl, hydroxymethyl, tetrahydropyranyloxymethyl, trityloxymethyl, propionyloxymethyl, amino, methylamino, aminomethyl, dimethylamino, carboxymethyl, allyloxycarbonylmethyl, allyloxycarbonylamino, methoxymethyl, ethoxymethyl, t-butoxymethyl, acetoxymethyl, chloromethyl, bromomethyl, iodomethyl, trifluoromethyl, 6-hydroxyhexyl, 2,4-dichloro(n-butyl), 2-aminopropyl, 1-chloroethyl, 2-chloroethyl, 1-bromoethyl, 2-chloroethyl, 1-fluoroethyl, 2-fluoroethyl, 1-iodoethyl, 2-iodoethyl, 1-chloropropyl, 2-chloropropyl, 3-chloropropyl, 1-bromopropyl, 2-bromopropyl, 3-bromopropyl, 1-fluoropropyl, 2-fluoropropyl, 3-fluoropropyl, 1-iodopropyl, 2-iodopropyl, 3-iodopropyl, 2-aminoethyl, 1-aminoethyl, N-benzoyl-2-aminoethyl, N-acetyl-2-aminoethyl, N-benzoyl-1-aminoethyl, N-acetyl-1-aminoethyl and the like.

**[0033]** The term "C<sub>1</sub> to C<sub>8</sub> substituted alkyl" denotes that the above C<sub>1</sub> to C<sub>8</sub> alkyl groups are substituted by one or more, and preferably one or two, halogen, hydroxy, protected hydroxy, oxo, protected oxo, C<sub>3</sub> to C<sub>7</sub> cycloalkyl, naphthyl,

amino, protected amino, (monosubstituted)amino, protected (monosubstituted)amino, (disubstituted)amino, guanidino, protected guanidino, heterocyclic ring, substituted heterocyclic ring, imidazolyl, indolyl, pyrrolidinyl, C<sub>1</sub> to C<sub>7</sub> alkoxy, C<sub>1</sub> to C<sub>7</sub> acyl, C<sub>1</sub> to C<sub>7</sub> acyloxy, nitro, carboxy, protected carboxy, carbamoyl, carboxamide, protected carboxamide, N-(C<sub>1</sub> to C<sub>6</sub> alkyl)carboxamide, protected N-(C<sub>1</sub> to C<sub>6</sub> alkyl)carboxamide, N,N-di(C<sub>1</sub> to C<sub>6</sub> alkyl)carboxamide, cyano, methylsulfonylamino, thiol, C<sub>1</sub> to C<sub>4</sub> alkylthio or C<sub>1</sub> to C<sub>4</sub> alkylsulfonyl groups. The substituted alkyl groups may be substituted once or more, and preferably once or twice, with the same or with different substituents.

**[0034]** The term "C<sub>7</sub> to C<sub>12</sub> phenylalkyl" denotes a C<sub>1</sub> to C<sub>6</sub> alkyl group substituted at any position by a phenyl, substituted phenyl, heteroaryl or substituted heteroaryl. Examples of such a group include benzyl, 2-phenylethyl, 3-phenyl(n-propyl), 4-phenylhexyl, 3-phenyl(n-amyl), 3-phenyl(sec-butyl) and the like. Preferred C<sub>7</sub> to C<sub>12</sub> phenylalkyl groups are the benzyl and the phenylethyl groups.

**[0035]** The term "C<sub>7</sub> to C<sub>12</sub> substituted phenylalkyl" denotes a C<sub>7</sub> to C<sub>12</sub> phenylalkyl group substituted on the C<sub>1</sub> to C<sub>6</sub> alkyl portion with one or more, and preferably one or two, groups chosen from halogen, hydroxy, protected hydroxy, oxo, protected oxo, amino, protected amino, (monosubstituted)amino, protected (monosubstituted)amino, (disubstituted)amino, guanidino, protected guanidino, heterocyclic ring, substituted heterocyclic ring, C<sub>1</sub> to C<sub>6</sub> alkyl, C<sub>1</sub> to C<sub>6</sub> substituted alkyl, C<sub>1</sub> to C<sub>7</sub> alkoxy, C<sub>1</sub> to C<sub>7</sub> substituted alkoxy, C<sub>1</sub> to C<sub>7</sub> acyl, C<sub>1</sub> to C<sub>7</sub> substituted acyl, C<sub>1</sub> to C<sub>7</sub> acyloxy, nitro, carboxy, protected carboxy, carbamoyl, carboxamide, protected carboxamide, N-(C<sub>1</sub> to C<sub>6</sub> alkyl)carboxamide, protected N-(C<sub>1</sub> to C<sub>6</sub> alkyl)carboxamide, N, N-(C<sub>1</sub> to C<sub>6</sub> dialkyl)carboxamide, cyano, N-(C<sub>1</sub> to C<sub>6</sub> alkylsulfonyl)amino, thiol, C<sub>1</sub> to C<sub>4</sub> alkylthio, C<sub>1</sub> to C<sub>4</sub> alkylsulfonyl groups; and/or the phenyl group may be substituted with one or more, and preferably one or two, substituents chosen from halogen, hydroxy, protected hydroxy, cyano, nitro, C<sub>1</sub> to C<sub>6</sub> alkyl, C<sub>1</sub> to C<sub>6</sub> substituted alkyl, C<sub>1</sub> to C<sub>7</sub> alkoxy, C<sub>1</sub> to C<sub>7</sub> substituted alkoxy, C<sub>1</sub> to C<sub>7</sub> acyl, C<sub>1</sub> to C<sub>7</sub> substituted acyl, C<sub>1</sub> to C<sub>7</sub> acyloxy, carboxy, protected carboxy, carboxymethyl, protected carboxymethyl, hydroxymethyl, protected hydroxymethyl, amino, protected amino, (monosubstituted)amino, protected (monosubstituted)amino, (disubstituted) amino, carboxamide, protected carboxamide, N-(C<sub>1</sub> to C<sub>6</sub> alkyl) carboxamide, protected N-(C<sub>1</sub> to C<sub>6</sub> alkyl) carboxamide, N, N-di(C<sub>1</sub> to C<sub>6</sub> alkyl)carboxamide, trifluoromethyl, N-((C<sub>1</sub> to C<sub>6</sub> alkyl)sulfonyl)amino, N-(phenylsulfonyl)amino, cyclic C<sub>2</sub> to C<sub>7</sub> alkylene or a phenyl group, substituted or unsubstituted, for a resulting biphenyl group. The substituted alkyl or phenyl groups may be substituted with one or more, and preferably one or two, substituents which can be the same or different.

**[0036]** Examples of the term "C<sub>7</sub> to C<sub>12</sub> substituted phenylalkyl" include groups such as 2-phenyl-1-chloroethyl, 2-(4-methoxyphenyl)ethyl, 4-(2,6-dihydroxy phenyl)n-hexyl, 2-(5-cyano-3-methoxyphenyl)n-pentyl, 3-(2,6-dimethylphenyl)n-propyl, 4-chloro-3-aminobenzyl, 6-(4-methoxyphenyl)-3-carboxy(n-hexyl), 5-(4-aminomethylphenyl)-3-(aminomethyl)n-pentyl, 5-phenyl-3-oxo-n-pent-1-yl and the like.

**[0037]** As outlined above R<sub>6</sub> and R<sub>7</sub> may be taken together with nitrogen to form a heterocycle or substituted heterocycle of the following kind aziridine, azetidine, pyrrolidine, 3-methylpyrrolidine, 3-aminopyrrolidine, 3-hydroxypyrrolidine, pyrazolidine, imidazolidine, piperidine, 2-methylpiperidine, piperazine, morpholine, azepine, tetrahydroisoquinoline

**[0038]** The term "heterocycle" or "heterocyclic ring" denotes optionally substituted five-membered to eight-membered rings that have 1 to 4 heteroatoms, such as oxygen, sulfur and/or nitrogen, in particular nitrogen, either alone or in conjunction with sulfur or oxygen ring atoms. These five-membered to eight-membered rings may be saturated, fully unsaturated or partially unsaturated, with fully saturated rings being preferred. Preferred heterocyclic rings include morpholino, piperidinyl, piperazinyl, 2-amino-imidazolyl, tetrahydrofurano, pyrrolo, tetrahydrothiophen-yl, hexylmethyleneimine and heptylmethyleneimine.

**[0039]** The term "substituted heterocycle" or "substituted heterocyclic ring" means the above-described heterocyclic ring is substituted with, for example, one or more, and preferably one or two, substituents which are the same or different which substituents can be halogen, hydroxy, protected hydroxy, cyano, nitro, C<sub>1</sub> to C<sub>12</sub> alkyl, C<sub>1</sub> to C<sub>12</sub> alkoxy, C<sub>1</sub> to C<sub>12</sub> substituted alkoxy, C<sub>1</sub> to C<sub>12</sub> acyl, C<sub>1</sub> to C<sub>12</sub> acyloxy, carboxy, protected carboxy, carboxymethyl, protected carboxymethyl, hydroxymethyl, protected hydroxymethyl, amino, protected amino, (monosubstituted)amino, protected (monosubstituted)amino, (disubstituted)amino carboxamide, protected carboxamide, N-(C<sub>1</sub> to C<sub>12</sub> alkyl)carboxamide, protected N-(C<sub>1</sub> to C<sub>12</sub> alkyl)carboxamide, N, N-di(C<sub>1</sub> to C<sub>12</sub> alkyl)carboxamide, trifluoromethyl, N-((C<sub>1</sub> to C<sub>12</sub> alkyl)sulfonyl)amino, N-(phenylsulfonyl)amino, heterocycle or substituted heterocycle groups.

**[0040]** The term "C<sub>1</sub> to C<sub>8</sub> alkoxy" as used herein denotes groups such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, t-butoxy and like groups. A preferred alkoxy is methoxy. The term "C<sub>1</sub> to C<sub>8</sub> substituted alkoxy" means the alkyl portion of the alkoxy can be substituted in the same manner as in relation to C<sub>1</sub> to C<sub>8</sub> substituted alkyl.

**[0041]** The term "C<sub>1</sub> to C<sub>8</sub> aminoacyl" encompasses groups such as formyl, acetyl, propionyl, butyryl, pentanoyl, pivaloyl, hexanoyl, heptanoyl, octanoyl, benzoyl and the like.

**[0042]** The term "C<sub>1</sub> to C<sub>8</sub> substituted aminoacyl" denotes the acyl group substituted by one or more, and preferably one or two, halogen, hydroxy, protected hydroxy, oxo, protected oxo, cyclohexyl, naphthyl, amino, protected amino, (monosubstituted)amino, protected (monosubstituted)amino, (disubstituted)amino, guanidino, heterocyclic ring, substituted heterocyclic ring, imidazolyl, indolyl, pyrrolidinyl, C<sub>1</sub> to C<sub>12</sub> alkoxy, C<sub>1</sub> to C<sub>12</sub> acyl, C<sub>1</sub> to C<sub>12</sub> acyloxy, nitro, C<sub>1</sub>

to C<sub>12</sub> alkyl ester, carboxy, protected carboxy, carbamoyl, carboxamide, protected carboxamide, N-(C<sub>1</sub> to C<sub>12</sub> alkyl) carboxamide, protected N-(C<sub>1</sub> to C<sub>12</sub> alkyl)carboxamide, N,N-di(C<sub>1</sub> to C<sub>12</sub> alkyl)carboxamide, cyano, methylsulfonylamino, thiol, C<sub>1</sub> to C<sub>10</sub> alkylthio or C<sub>1</sub> to C<sub>10</sub> alkylsulfonyl groups. The substituted acyl groups may be substituted once or more, and preferably once or twice, with the same or with different substituents.

**[0043]** Examples of C<sub>1</sub> to C<sub>8</sub> substituted acyl groups include 4-phenylbutyroyl, 3-phenylbutyroyl, 3-phenylpropanoyl, 2-cyclohexanylacetyl, cyclohexanecarbonyl, 2-furanoyl and 3-dimethylaminobenzoyl.

**[0044]** This invention provides a pharmaceutical composition comprising an effective amount of a compound according to the invention. Such compounds can be administered by various routes, for example oral, subcutaneous, intramuscular, intravenous or intracerebral. The preferred route of administration would be oral at daily doses of the compound for adult human treatment of about 0.01 -5000 mg, preferably 1-1500 mg per day. The appropriate dose may be administered in a single dose or as divided doses presented at appropriate intervals for example as two, three four or more subdoses per day.

**[0045]** For preparing pharmaceutical compositions containing compounds of the invention, inert, pharmaceutically acceptable carriers are used. The pharmaceutical carrier can be either solid or liquid. Solid form preparations include, for example, powders, tablets, dispersible granules, capsules, cachets, and suppositories.

**[0046]** A solid carrier can be one or more substances which can also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, or tablet disintegrating agents; it can also be an encapsulating material.

**[0047]** In powders, the carrier is generally a finely divided solid which is in a mixture with the finely divided active component. In tablets, the active compound is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.

**[0048]** For preparing pharmaceutical composition in the form of suppositories, a low-melting wax such as a mixture of fatty acid glycerides and cocoa butter is first melted and the active ingredient is dispersed therein by, for example, stirring. The molten homogeneous mixture is then poured into convenient-sized molds and allowed to cool and solidify.

**[0049]** Powders and tablets preferably contain between about 5% to about 70% by weight of the active ingredient. Suitable carriers include, for example, magnesium carbonate, magnesium stearate, talc, lactose, sugar, pectin, dextrin, starch, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, a low-melting wax, cocoa butter and the like.


**[0050]** The pharmaceutical compositions can include the formulation of the active compound with encapsulating material as a carrier providing a capsule in which the active component (with or without other carriers) is surrounded by a carrier, which is thus in association with it. In a similar manner, cachets are also included. Tablets, powders, capsules, and capsules can be used as solid dosage forms suitable for oral administration.

**[0051]** Liquid pharmaceutical compositions include, for example, solutions suitable for oral or parenteral administration, or suspensions, and emulsions suitable for oral administration. Sterile water solutions of the active component or sterile solutions of the active component in solvents comprising water, ethanol, or propylene glycol are examples of liquid compositions suitable for parenteral administration.

**[0052]** Sterile solutions can be prepared by dissolving the active component in the desired solvent system, and then passing the resulting solution through a membrane filter to sterilize it or, alternatively, by dissolving the sterile compound in a previously sterilized solvent under sterile conditions.

**[0053]** In one embodiment of the present invention a compound is claimed according to formula (1) above, or pharmaceutical acceptable salts or solvates thereof, wherein R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, is H, halogen, hydroxy, protected hydroxy, cyano, nitro, C<sub>1</sub> to C<sub>6</sub> alkyl, C<sub>1</sub> to C<sub>6</sub> substituted alkyl, C<sub>1</sub> to C<sub>7</sub> alkoxy, C<sub>1</sub> to C<sub>7</sub> substituted alkoxy, C<sub>1</sub> to C<sub>7</sub> acyl, C<sub>1</sub> to C<sub>7</sub> substituted acyl, C<sub>1</sub> to C<sub>7</sub> acyloxy, carboxy, protected carboxy, carboxymethyl, protected carboxymethyl, hydroxymethyl, protected hydroxymethyl, amino, protected amino, (monosubstituted)amino, protected (monosubstituted) amino, (disubstituted)amino, carboxamide, protected carboxamide, N-(C<sub>1</sub> to C<sub>6</sub> alkyl)carboxamide, protected N-(C<sub>1</sub> to C<sub>6</sub> alkyl)carboxamide, N, N-di(C<sub>1</sub> to C<sub>6</sub> alkyl)carboxamide, trifluoromethyl, N-((C<sub>1</sub> to C<sub>6</sub> alkyl)sulfonyl)amino, N-(phenylsulfonyl)amino or phenyl, R<sub>5</sub> is H, C<sub>1</sub> to C<sub>8</sub> alkyl, C<sub>1</sub> to C<sub>8</sub> substituted alkyl, C<sub>7</sub> to C<sub>12</sub> alkylphenyl or C<sub>7</sub> to C<sub>12</sub> substituted phenylalkyl, R<sub>6</sub> and R<sub>7</sub> may be taken together with nitrogen to form the heterocycle according to formula (2),


formula (2)



**[0054]** In a preferred embodiment of the invention a compound is provided, or pharmaceutical acceptable salts or solvates thereof, wherein  $R_1$ ,  $R_2$ ,  $R_3$ ,  $R_4$ , is H, halogen, hydroxy, protected hydroxy, cyano, nitro,  $C_1$  to  $C_6$  alkyl,  $C_1$  to  $C_6$  substituted alkyl,  $C_1$  to  $C_7$  alkoxy,  $C_1$  to  $C_7$  substituted alkoxy,  $C_1$  to  $C_7$  acyl,  $C_1$  to  $C_7$  substituted acyl,  $C_1$  to  $C_7$  acyloxy, carboxy, protected carboxy, carboxymethyl, protected carboxymethyl, hydroxymethyl, protected hydroxymethyl, amino, protected amino, (monosubstituted)amino, protected (monosubstituted)amino, (disubstituted)amino, carboxamide, protected carboxamide, N-( $C_1$  to  $C_6$  alkyl)carboxamide, protected N-( $C_1$  to  $C_6$  alkyl)carboxamide, N, N-di( $C_1$  to  $C_6$  alkyl)carboxamide, trifluoromethyl, N-(( $C_1$  to  $C_6$  alkyl)sulfonyl)amino, N-(phenylsulfonyl)amino or phenyl,  $R_5$  is H,  $C_1$  to  $C_8$  alkyl,  $C_1$  to  $C_8$  substituted alkyl,  $R_6$  and  $R_7$  may be taken together with nitrogen to form the heterocycle according to formula (2) shown above.


**[0055]** A particularly preferred compound which may act as agonist of LXR is shown in formula (6) below. The inventors have been able to demonstrate that the compound according to formula (3) has a low effective concentration at LXR with an  $EC_{50}$  of 0.5  $\mu$ M wherein the  $EC_{50}$  reflects the half-maximal effective concentration, and which is higher than the  $EC_{50}$  of 0.015  $\mu$ M for the published LXR agonist TO901317 (J. Schultz et al., Genes Dev. 14, 2831-2838, 2000)

formula (3) (MOLNAME 3252)




**[0056]** The inventors have also found the compounds according to formula (4, 5 and 6) (shown below) to be active as agonist of the LXR human nuclear receptor (see figures for details).

formula (4) (MOLNAME 7459)




formula (5) (MOLNAME 6584)





formula (6) (MOLNAME 7364)



**[0057]** In particular the invention relates to a compound as described above wherein said compounds is capable of binding the LXR receptor protein or a portion thereof according to SEQ ID NO. 1 (Fig. 3 A to F) or a mammalian homologue thereof. The claimed compound can bind to the LXR receptor protein or a portion thereof in a mixture comprising 10-200 ng of LXR receptor protein, a fusion protein containing LXR or a portion thereof, preferably the ligand binding domain, fused to a Tag, 5-100 mM Tris /HCl at pH 6,8-8,3 ; 60-1000 mM KCl; 0-20 mM MgCl<sub>2</sub>; 100-1000ng/μl BSA in a total volume of preferably about 25 μl.).

**[0058]** A mammalian receptor protein homologue of the protein according to SEQ ID NO. 1 as used herein is a protein that performs substantially the same task as LXR does in humans and shares at least 40% sequence identity at the amino acid level, preferably over 50 % sequence identity at the amino acid level more preferably over 65 % sequence identity at the amino acid level, even more preferably over 75 % sequence identity at the amino acid level and most preferably over 85 % sequence identity at the amino acid level.

**[0059]** The invention in particular concerns a method for prevention or treatment of a LXR receptor protein or LXR receptor protein homologue mediated disease or condition in a mammal comprising administration of a therapeutically effective amount of a compound according to the invention wherein the prevention or treatment is directly or indirectly accomplished through the binding of a compound according to the invention to the LXR receptor protein or to the LXR receptor protein homologue.

**[0060]** The term mediated herein means that the physiological pathway in which the LXR receptor protein acts is either directly or indirectly involved in the disease or condition to be treated or prevented. In the case where it is indirectly involved it could be that, e.g. modulating the activity of LXR by a compound according to the invention influences a parameter which has a beneficial effect on a disease or a condition. One such example is that modulation of LXR activity leads to decreased levels of serum cholesterol or certain lipoproteins which in turn have a beneficial effect on the prevention and treatment of atherosclerosis. Herein a condition is a physiological or phenotypic state which is desirably altered. One such example would be obesity which is not necessarily medically harmful but nonetheless a non desirable phenotypic condition. In a preferred embodiment of the invention the method for prevention or treatment of a LXR receptor protein mediated disease or condition is applied to a human. This may be male or female.

**[0061]** Pharmaceutical compositions generally are administered in an amount effective for treatment or prophylaxis of a specific condition or conditions. Initial dosing in human is accompanied by clinical monitoring of symptoms, such symptoms for the selected condition. In general, the compositions are administered in an amount of active agent of at least about 100 μg/kg body weight. In most cases they will be administered in one or more doses in an amount not in excess of about 20 mg/kg body weight per day. Preferably, in most cases, doses is from about 100 μg/kg to about 5 mg/kg body weight, daily.

**[0062]** For administration particularly to mammals, and particularly humans, it is expected that the daily dosage level of active agent will be 0,1 mg/kg to 10 mg/kg and typically around 1 mg/kg.

**[0063]** By "therapeutically effective amount" is meant a symptom- alleviating or symptom -reducing amount, a cholesterol-reducing amount, a cholesterol absorption blocking amount, a protein and/or carbohydrate digestion-blocking amount and/or a de novo cholesterol biosynthesis blocking amount of a compound according to the invention.

**[0064]** Likewise, the invention concerns a method of treating in mammal a disease which is correlated with abnormal cholesterol, triglyceride, or bile acid levels or deposits comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound according to the invention.

**[0065]** Accordingly, the compounds according to the invention may also be used as a method of prevention or treatment of mammalian atherosclerosis, gallstone disease, lipid disorders, Alzheimer's disease, skin disorders, obesity or cardiovascular disorders such as coronary heart disease or stroke.

**[0066]** The invention further concerns a method of blocking in a mammal the cholesterol absorption in the intestine in need of such blocking comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound according to the invention. The invention may also be used to treat obesity in humans.

**[0067]** The Liver X Receptor alpha is a prototypical type 2 nuclear receptor meaning that it activates genes upon binding to the promoter region of target genes in a heterodimeric fashion with Retinoid X Receptor. The relevant physiological ligands of LXR are oxysterols. The present compounds according to the invention have been demonstrated to have a high binding efficacy (binding coefficients measured as EC<sub>50</sub> in the range 100 nM to 1500 nM) as well as agonistic and / or antagonistic properties. Consequently they may be applied to regulate genes that participate in bile acid, cholesterol and fatty acid homeostasis as well as other downstream regulated genes. Examples of such genes are but are not limited to lipid absorption, cholesterol biosynthesis, cholesterol transport or binding, bile acid transport or binding, proteolysis, amino acid metabolism, glucose biosynthesis, protein translation, electron transport, and hepatic fatty acid metabolism. LXR often functions in vivo as a heterodimer with the Retinoid X Receptor. Published LXR agonists such as the Tularik compound "TO901317" (See figure 5) are known to influence the regulation of various liver genes. Genes found to be regulated by TO901317 can be found in figure 6. Thus, the invention also concerns a method of modulating a gene whose expression is regulated by the LXR receptor in a mammal comprising administration of a therapeutically effective amount of a compound according to the invention to said mammal.

**[0068]** A number of direct and indirect LXR target genes have been described whose regulated expression contribute to cholesterol homeostasis and lipogenesis. In this respect the direct regulation of Cyp7A, which was shown to be a direct target gene of LXR at least in the rodent lineage is an important aspect of cholesterol removal by increased metabolism of bile acids (Lehmann et al., J Biol.Chem. 272 (6) 3137-3140; 1007). Gupta et al. (Biochem. Biophys. Res. Com, 293; 338-343, 2002) showed that LXR  $\alpha$  regulation of Cyp7A is dominant over FXR inhibitory effects on Cyp7A transcription.

**[0069]** A key transcription factor that was also shown to be a direct target gene for the LXR receptor is SREBP-1C (Repa et al., Genes and Development, 14:2819-2830; 2000; Yoshikawa et al.; Mol.Cell.Biol.21 (9) 2991-3000, 2001). SREBP-1C itself activates transcription of genes involved in cholesterol and fatty acid synthesis in liver but also other mammalian tissues. Some of the SREBP1c target genes involved in lipogenesis like FAS and SCD have shown to be additionally direct targets of the LXR receptors (Joseph et al.; J Biol Chem. 2002 Mar 29;277(13):11019-25; Liang et al., J Biol Chem. 2002 Mar 15;277(11):9520-8.).

**[0070]** Another gene that has been shown to be directly regulated by LXRs is the LPL gene, that codes for a key enzyme that is responsible for the hydrolysis of triglycerides in circulating lipoprotein, releasing free fatty acids to peripheral tissues. (Zhang et al. J Biol Chem. 2001 Nov 16;276(46):43018-24.) This enzyme is believed to promote uptake of HDL cholesterol in liver, thereby promoting reverse cholesterol transport. A similar functional involvement in HDL clearance is described for the CETP gene product that facilitated the transfer of HDL cholesterol esters from plasma to the liver. LXR response elements were found in the CETP promoter and direct activation of this gene by LXR was demonstrated (Luo and Tall; J Clin Invest. 2000 Feb;105(4):513-20.).

**[0071]** The regulated transport of cholesterol through biological membranes is an important mechanism in order to maintain cholesterol homeostasis. A pivotal role in these processes in multiple tissues like e.g. macrophages and intestinal mucosa cells is maintained by the ATPbinding cassette transporter proteins (ABC). ABCA1 and ABCG1 were identified as direct LXR target genes (Costet et al.; J Biol Chem. 2000 Sep 8;275(36):28240-5) that mediate cholesterol efflux and prevent thereby e.g. generation of atherogenic plaques in macrophages (Singaraja et al. J Clin Invest. 2002 Jul;110(1):35-42). Other ABC transporters like ABCG5 and ABCG8 , primarily expressed in hepatocytes and enterocytes have also been reported to be directly responsive to LXR agonists ( Repa et al., J Biol Chem. 2002 May 24;277 (21):18793-800. Kennedy et al., J Biol Chem. 2001 Oct 19;276(42):39438-47) and mediate the secretion of sterols from the liver and efflux of dietary sterols from the gut.

**[0072]** Apolipoproteins E, C-I, C-II, and C-IV, that fulfill important roles in lipoprotein/lipid homeostasis have also been shown to be direct targets of the LXR receptor ( Laffitte et al., Proc Natl Acad Sci U S A. 2001 Jan 16;98(2): 507-12; Mak et al.; J Biol Chem. 2002 May 24 [epub ahead of print]). These proteins have been found to be crucial components of chylomicrons, VLDL, IDL, and HDL and are among other things associated with hypertriglyceridemia and arteriosclerosis.

**[0073]** Recently the LXR $\alpha$  itself was shown to be regulated by both LXR receptors in human cell types including macrophages suggesting an autoregulatory amplification event in the response to LXR ligands which could e.g. lead to an enhanced stimulation of LXR target genes like e.g. ABCA1 (Bolten et al.; Mol Endocrinol. 2002 Mar;16(3):506-14.; Laffitte et al., Mol Cell Biol. 2001 Nov;21(22):7558-68; Whitney et al.; J Biol Chem. 2001 Nov 23;276(47):43509-15).

**[0074]** Besides the important function of LXR receptors in tissues like liver and macrophages it has recently been reported that that stimulation of epidermal differentiation is mediated by Liver X receptors in murine epidermis. Differentiation marker genes like involucrin, loricin and profilaggrin have been shown to be upregulated upon LXR ligand treatment (Kömüves et al.; J Invest Dermatol. 2002 Jan;118(1):25-34.).

**[0075]** Another recent report describes the regulation of cholesterol homeostasis (primarily the regulation of ABCA1, ABCG1 and SREBP-1C) by the LXR receptors in the central nervous system suggesting that LXRs may prove beneficial in the treatment of CNS diseases such as Alzheimer's and Niemann-Pick disease that are known to be accompanied by dysregulation of cholesterol balance (Whitney et al.; Mol Endocrinol. 2002 Jun;16(6):1378-85).

**[0076]** Therefore one important embodiment the invention concerns are methods that enhances or suppresses amongst other today yet unknown LXR target genes the above mentioned genes and the associated biological processes and pathways through LXR compounds that are subject of this invention.

**[0077]** The compounds according to the invention may be used as medicaments, in particular for the manufacture of a medicament for the prevention or treatment of a LXR receptor protein or LXR receptor protein homologue mediated disease or condition in a mammal wherein the prevention or treatment is directly or indirectly accomplished through the binding of the compound according to the invention to the LXR receptor protein or LXR receptor protein homologue. These pharmaceutical compositions contain 0,1 % to 99,5 % of the compound according to the invention, more particularly 0,5 % to 90 % of the compound according to the invention in combination with a pharmaceutically acceptable carrier.

**[0078]** The invention concerns also the use of a compound according to the invention for the manufacture of a medicament for the prevention or treatment of a LXR receptor protein mediated disease or condition wherein the mammal described above is a human. The medicament may be used for regulating the cholesterol transport system, for regulating levels of cholesterol, triglyceride, and/or bile acid in a mammal preferentially a human by activating the LXR receptor. The medicament may be used for the treatment of atherosclerosis, gallstone disease, lipid disorders, Alzheimer's disease, skin disorders, obesity or a cardiovascular disorder.

**[0079]** The further concerns the use of a compound according to the invention for the manufacture of a medicament capable for blocking in a mammal, preferentially a human the cholesterol absorption in the intestine. Further the claimed compound may be used for the manufacture of a medicament for treating obesity in humans and for modulating a gene whose expression is regulated by the LXR receptor (see details above and figures).

**[0080]** The present invention shall now be further illustrated based on the following examples without being limited thereto. In the accompanying sequence protocol and the figures:

SEQ ID NO. 1 shows protein sequence of the LXR $\alpha$  protein a portion of which was used for cloning as described in the examples,

SEQ ID NO. 2 shows the mRNA sequence of the LXR $\alpha$  protein,

SEQ ID NO. 3 shows the protein sequence of TIF2 (Acc. No: XM\_011633 RefSeq DB),

SEQ ID NO. 4 shows the respective mRNA sequence corresponding to the TIF2 protein,

SEQ ID NO 5 shows the protein sequence of the LXR $\beta$  protein a portion of which was used for cloning as described in examples,

SEQ ID NO 6 shows the mRNA sequence of the LXR $\beta$  protein,

SEQ ID NO 7 shows the sequence of primer (a) used in Example 1

SEQ ID NO 8 shows the sequence of primer (b) used in Example 1.

**[0081]** Fig. 1 shows the synthesis of the compounds according to the invention as also described in Example 2.

**[0082]** Fig. 2 shows the measurement parameters employed by the Wallace VICTOR2V™ Multilabel Counter which was used for measuring the EC<sub>50</sub> values

**[0083]** Fig. 3 A shows SEQ ID NO. 1 which is the protein sequence of the LXR $\alpha$  protein a portion of which was used for cloning as described in the examples. Figure 3 B shows SEQ ID NO. 2 which is the mRNA sequence of the

LRX alpha protein. Figure 3 C shows SEQ ID NO. 3 which is the protein sequence of TIF2 (Acc. No: XM\_011633 RefSeq DB), Figure 3 D shows SEQ ID NO. 4 which is the respective mRNA sequence corresponding to the TIF2 protein. Figure 3 E shows SEQ ID NO 5 which is the protein sequence of the LXR beta protein a portion of which was used for cloning as described in examples. Figure 3 F shows SEQ ID NO 6 which is the mRNA sequence of the LXR beta protein.

[0084] Fig. 4 shows the internal molecular name used by the applicant (MOLNAME) as well as the corresponding structures of preferred compounds according to the invention. The figure further shows their respective EC<sub>50</sub> values (EC<sub>50</sub> AVG) as established according to the experiment 1 in multiple experiments (see above), as well as their respective average efficacy (% activity relative to 22-(R)-hydroxycholesterol control agonist).

[0085] Figure 5 shows various known LXR ligands. It is apparent from their structures that the inventors have identified novel compounds which are structurally not related to these known ligands.

[0086] Figure 6 shows various genes that have been found to be regulated through binding of an LXR agonist to the LXR protein.

[0087] Figure 7 shows a dose-dependent transactivation (EC<sub>50</sub> ~ 3 μM) by LN0000007465 of the luciferase reporter gene via LXR alpha.

[0088] Figure 8 shows (A) Analysis of mRNA content of the indicated genes in total RNA isolated from THP-1 cells treated for 24 hours with 2, 10 or 25 μM of LN0000006500 or 10 μM of the Tularik compound (T0901317). (B) Analysis of mRNA content to the indicated genes in total RNA from HepG2 cells treated for 24 hours with 2, 10 or 25 μM of LN0000006500 or 10 μM of the Tularik compound (T0901317).

[0089] Figure 9 shows the dose dependent transactivation by LN0000006500 of the pFR-luc reporter gene in CHO cells via Gal4 LBD-fusion constructs derived from LXRA- or LXRB. Concentrations of the compound administered (μM) and RLU's determined from extracts of cells are indicated.

[0090] Figure 10 shows the analysis of total cholesterol from supernatants of cultivated THP-1 cells incubated without or with ApoA1 and ApoA1 plus 10 μM of the compounds Tularik (T0901317) or LN0000006500, LN0000006662, LN0000006671 or LN0000006672 as indicated.

## EXAMPLES

### EXAMPLE 1:

[0091] In vitro screening for compounds which influence LXR binding to coactivators.

For screening purposes a GST and 6 x His fusion of the LBD (from amino acids 155 of hLXRalpha to 447) of human LXRalpha was constructed by first cloning a Gateway cassette (Invitrogen) in frame into the Sma I site of the pACGHLT Polylinker (Pharmingen). Then a PCR fragment specifically amplified from human liver cDNA was cloned into the resulting pACGHLT-GW following the manufacturers instructions for Gateway cloning (Invitrogen) to yield pACGHLT-GW-hLXRalphaLBD.

Primers used for amplification were: primer (a)  
GGGGACAAGTTTGTACAAAAAAGCAGGCTCGCTTCGCAAATGCCGTCAG (SEQ ID  
NO 7), and primer (b)  
GGGGACCACTTTGTACAAGAAAGCTGGGTCCCCTTCTCAGTCTGTTCCACTT (SEQ  
ID NO 8).

[0092] 100 % sequence integrity of all recombinant products was verified by sequencing. Recombinant Baculovirus was constructed from pACGHLT-GW-hLXRalphaLBD using the Pharmingen Baculovirus Expression vector system according to instructions of the manufacturer. Monolayer cultures of SF9 cells were infected by the virus as recommended by Pharmingen or 200ml cultures of 1 x 10<sup>6</sup> cells/ml grown in 2 liter Erlenmeyer flasks on an orbital shaker at 30 rpm were infected by 10ml of same virus stock. In both cases cells were harvested 3 days after infection. All cell growth was performed in Gibco SF900 II with Glutamine (Invitrogen) medium without serum supplementation at 28°C. Since SF9 cells contain significant amounts of endogenous GST, purification was performed via His and not via GST affinity chromatography. To this end instructions of Pharmingen for purification of recombinant His tagged proteins from SF9 cells were followed with the following modifications: All detergents were omitted from the buffers and cells were lysed on ice by 5 subsequent sonication pulses using a sonicator needle at maximum power.

[0093] All eluates were dialyzed against 20 mM Tris/HCl pH 6,8, 300 mM KCl; 5 mM MgCl<sub>2</sub>; 1 mM DTT; 0,2 mM

PMSF; 10% Glycerol. A typical dialyzed eluate fraction contained the fusion protein at a purity of more than 80%. Total protein concentration was 0,1-0,3 mg/ml.

**[0094]** For E. coli expression of a NR coactivator, pDest17-hTif2BD expressing a NR interaction domain from amino acids 548-878 of human Tif2 (Acc. No: XM\_011633 RefSeq) tagged by 6 N-terminal His residues was constructed. Therefore, a PCR fragment specifically amplified from human liver cDNA was subcloned into pDest 17 (Invitrogen) following the manufacturers instructions for Gateway cloning (Invitrogen). Primers used for Amplification were: primer (a)

GGGGACAAGTTTGTACAAAAAAGCAGGCTCGTTAGGGTCATCGTTGGCTTCACC

and primer (b)

GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAAAGTTGCCCTGGTCGTGGGTTA

**[0095]** For E. coli expression plasmid DNA was transformed into chemically competent E. coli BL21 (Invitrogen, USA) and cells were grown to an OD600 of 0.4-0.7 before expression was induced by addition of 0,5 mM IPTG according to instructions of the manufacturer (Invitrogen). After induction for 8 hours at 30°C cells were harvested by centrifugation for 10 minutes at 5000 x g. Fusion proteins were affinity purified using Ni-NTA Agarose (QIAGEN) according to the instructions of the manufacturer. Recombinant Tif2 construct was dialyzed against 20 mM Tris/HCL pH 7.9; 60 mM KCl; 5 mM MgCl<sub>2</sub>; 1 mM DTT, 0,2 mM PMSF; 10% glycerol. A typical dialyzed eluate fraction contained the fusion protein at a purity of more than 80%. Total protein concentration was 0,1-0,3 mg/ml.

**[0096]** The TIF2 fragment was subsequently biotinylated by addition of 5-40 µl/ml Tif2 fraction of a Biotinamidocaproate N-Hydroxysuccinimide-ester (Sigma) solution (20 mg/ml in DMSO). Overhead rotating samples were incubated for 2 hours at room temperature. Unincorporated label was then separated using G25 Gel filtration chromatography (Pharmacia Biotech, Sweden). Protein containing fractions from the column were pooled and tested for activity in the assay as described below.

**[0097]** For screening of compound libraries as provided for by the methods shown below in the examples for substances which influence the LXR/Tif 2 interaction, the Perkin Elmer LANCE technology was applied. This method relies on the binding dependent energy transfer from a donor to an acceptor fluorophore attached to the binding partners of interest. For ease of handling and reduction of background from compound fluorescence LANCE technology makes use of generic fluorophore labels and time resolved detection (for detailed description see Hemmälä I, Blomberg K and Hurskainen P, Time-resolved resonance energy transfer (TR-FRET) principle in LANCE, Abstract of Papers Presented at the 3rd Annual Conference of the Society for Biomolecular Screening, Sep., California (1997) )

**[0098]** For screening, 20-200 ng of biotinylated Tif 2 fragment and 10-200 ng of GST-LXR fragment were combined with 0.5-2 nM LANCE Eu-(W1024) labelled anti-GST antibody (Perkin Elmer) and 0,1-0,5 µg of highly fluorescent APC-labelled streptavidin (Perkin Elmer, AD0059) in the presence of 50 µM of individual compounds to be screened in a total volume of 25 µl of 20 mM Tris /HCl pH 6,8; 300 mM KCl; 5 mM MgCl<sub>2</sub>; 100-1000 ng/µl/ BSA DMSO content of the samples was kept below 4%. Samples were incubated for a minimum of 60 minutes in the dark at room temperature in FIA-Plates black 384well med. binding (Greiner).

**[0099]** The LANCE signal was detected by a Perkin Elmer VICTOR2V™ Multilabel Counter applying the detection parameters listed in Fig. 2. The results were visualized by plotting the ratio between the emitted light at 665 nm and at 615 nm. For every batch of recombinant proteins amount of proteins, including BSA and labeling reagents giving the most sensitive detection of hits was determined individually by analysis of dose response curves for 22R Hydrox-cholesterol and TO 901317

## EXAMPLE 2:

**[0100]** Experimental procedure for the preparation of the compounds according to the invention.

### o-AZIDOBENZOIC ACID SYNTHESIS (2)

**[0101]** The anthranilic acid (1, 1 eq., 0.5-1 M) was suspended in 6 M HCl, containing enough AcOH (0-20% dependent upon the anthranilic acid) to facilitate dissolution of the anthranilic acid and/or the intermediate diazonium salt, and cooled to 0 °C. NaNO<sub>2</sub> (1.1 eq., 1.3-2.5 M) dissolved in H<sub>2</sub>O was added to the anthranilic acid solution at a rate such

that the temperature of the reaction solution remained below 5 °C. The resulting homogeneous solution of the diazonium salt was slowly filtered through a sintered glass funnel into a solution of NaN<sub>3</sub> (1.1 eq., 0.7-1.1 M) and NaOAc (12 eq.) in H<sub>2</sub>O. The reaction mixture was stirred/shaken for 30-60 min following cessation of vigorous N<sub>2</sub> evolution. Following acidification of the reaction mixture to pH 1 with concentrated HCl, the mixture was cooled to 0 °C to encourage complete precipitation of the *o*-azidobenzoic acid. The precipitate was collected by filtration and washed with 6 M HCl (2x) and H<sub>2</sub>O (2x). The *o*-azidobenzoic acid product (2) was dried *in vacuo* (500 mtorr, 30 °C).

#### ACYLATION OF HYDROXYMETHYL RESIN (4)

**[0102]** To hydroxymethyl resin (1.0 eq., 1.3 mmol/g) and the *o*-azidobenzoic acid (1, 2.5 eq.) was added DMF (to give 400 mM *o*-azidobenzoic acid, 1), CsCO<sub>3</sub> (2.0 eq.) and KI (2.0 eq.). Following agitation of the reaction mixture for 36-48 h, the resin-bound *o*-azidobenzoic acid (4) was washed with MeOH (2 cycles), CH<sub>2</sub>Cl<sub>2</sub> (3 cycles), MeOH (3 cycles), DMF (3 cycles), MeOH (3 cycles) and CH<sub>2</sub>Cl<sub>2</sub> (3 cycles), and dried *in vacuo*.

#### AZA-WITTIG FORMATION (5)

**[0103]** To the resin-bound *o*-azidobenzoic acid (4, 1.0 eq.) was added a solution of PPh<sub>3</sub> (THF, 500 mM, 5.0 eq.). After 6 h, the resin was washed with 3 cycles of the following: THF (3 cycles), toluene (3 cycles), CH<sub>2</sub>Cl<sub>2</sub> (3 cycles) and hexanes (3 cycles). Followed by drying *in vacuo* to afford resin bound iminophosphorane (5)

#### CARBODIIMIDE FORMATION (6)

**[0104]** To the resin-bound iminophosphorane (5, 1 eq.) was added isocyanate (9, 5 eq., 450 mM) dissolved in ClCH<sub>2</sub>CH<sub>2</sub>Cl. The compounds were shaken at ambient temperature for 16 h, washed with 3 cycles of the following: THF (3 cycles), toluene (3 cycles), CH<sub>2</sub>Cl<sub>2</sub> (3 cycles) and hexanes (3 cycles), and dried *in vacuo* to afford carbodiimide (6).

#### GUANIDINE FORMATION / CYCLIZATION

**[0105]** To the carbodiimide functionalized resin (6) was added secondary amine (10, 0.6 eq., 500 mM) dissolved in ClCH<sub>2</sub>CH<sub>2</sub>Cl. The reaction mixture was heated to 50 °C in an incubator for 12-72 h to afford 2-aminoquinazoline (8).

**[0106]** All of the final products were analyzed by HPLC using mass and an Evaporative Light Scattering Detector (ELSD) detection to determine purity and identity.

**[0107]** One skilled in the art will be able to arrive at the compounds claimed herein making use of said protocol.

#### EXAMPLE 3:

**[0108]** This example illustrates that a compound according to the invention (experiments shown were done with MOLSTRUCTURE LN 0000007465 (see figures 4 for structural formula)) can mediate transactivation of LXR mediated transcription in HEK293 cells.

**[0109]** HEK293 cells were grown in 48 well plates and co-transfected with the pTrexDest30 (Invitrogen) derivatives pTrexDest30-hLXRα, pTrexDest30-hRXRα and the pGL2promoter (Promega) derivative pGL2promoter-LXRRE (each 300 ng of plasmid DNA). The full length human LXR (accession U68233) and the full length human RXRα (accession P19793) were cloned into the pTrexDest30 applying the manufacturer protocols for the Gateway™ system (Invitrogen).

**[0110]** The LXR response elements (LXRRE) were (upper case and underlined) 5' CccttTGGTCActcaAGTTCAagtgtatagataattcgatccttTGGTCActcaAGTTCAagtga 3' (SEQ ID NO. 5) derived from the rat Cyp7a promoter (Laffite et al., 2001, PNAS 98, pp 507). Luciferase reporter activity was measured in triplicates from extracts of cells after incubating cells in culture medium (DMEM [Gibco-BRL] + 10% FCS [PAA laboratories]) for 16 hours (5% CO<sub>2</sub>, 37°C) containing 0.5% DMSO (control) or 0.5% DMSO with increasing concentrations of LN0000007465.

**[0111]** A dose-dependent transactivation (EC<sub>50</sub> ~ 3 μM) of the reporter gene by LXRα was observed (Fig. 7).

#### Example 4:

**[0112]** This example shows that described compounds can increase the abundance of mRNA of target genes for the LXR proteins in THP-1 cells treated with TPA.

**[0113]** THP-1 (3x10<sup>5</sup> cells per dish) cells were seeded in 24 well dishes in 3 ml modified RPMI-1640 medium (ATTC,

Cat.No. 30-2001) containing 10%FCS (GIBCO) and 100nM TPA and cultivated at 37°C in 5% CO<sub>2</sub> for 48 hours. The medium was then removed and replaced with medium containing 10% charcoal/stripped FBS (Hyclone) and incubated with LN0000006500 at 2, 10 or 25 µM concentration or Tularik (T0901317) at 10 µM for 24 hours as indicated in Fig 8A as an example. HepG2 (4,5x10<sup>5</sup> cells per dish) were seeded in 24 well dishes in 3 ml DMEM Medium containing 10%FCS (GIBCO) and cultivated at 37°C in 5% CO<sub>2</sub> for 48 hours as indicated in Fig 8B.

**[0114]** After incubation for 24 hours in presence of compound, total RNA was isolated from the cells using a Quiagen RNAeasy kit (Quiagen) according to the manufacturers protocol. The RNA was then reverse transcribed and analyzed by TaqMan Analysis using kits and equipment from Perkin-Elmer known to those knowledgeable in the field.

**[0115]** The fold change of mRNA abundancy of compound treated versus DMSO treated as a control is shown in Figure 8A and B for several analyzed target genes indicated in Figure 8A and B.

Example 5:

**[0116]** This example shows that described compounds can selectively enhance transcription mediated by the LBD's of the respective nuclear receptors LXRα and LXRβ.

**[0117]** CHO cells (1x10<sup>5</sup> cells 96well plate) were co-transfected (Lipofectamine 2000 GIBCO) with pFR-luc (Stratagene) as a reporter gene construct and pCMV-AD derivatives containing the LXRα or LXRβ ligand binding domains, which were cloned via the gateway system (GIBCO) described in Example 1, in order to express Gal4DBD-LXRα or Gal4DBD-LXRβ fusion proteins.

**[0118]** Cells were grown in DMEM containing 10%FCS at 37°C in 5% humidified CO<sub>2</sub> for 16h in presence of 0,05% DMSO vehicle or 0,032 to 50 µM LN0000006500 in vehicle (as indicated in Fig.9). Luciferase activity was determined from aliquots of extracts prepared from cells following standard luciferase assay kits and protocols from Promega.

Example 6:

**[0119]** This example shows that described compounds at 10 µM concentration for 24 hours can increase the reverse cholesterol transport in THP-1 cells that were treated with TPA.

**[0120]** THP-1 (1x10<sup>6</sup> cells per dish) cells were seeded in 6 well dishes in 3ml modified RPMI1640 medium (ATCC, Cat.No. 30-2001) containing 10%FCS (GIBCO) and 100nM TPA and cultivated at 37°C in 5% CO<sub>2</sub> for 72 hours. The medium was then removed and replaced with fresh medium containing 100 nM TPA and 0,15 % BSA. After 24 h incubation the cells were washed in PBS and 1,5 ml of fresh medium containing either 0,1% DMSO alone or 0,1% DMSO together with 40µg/ml ApoA1 (Calbiochem) or 40µg/ml ApoA1 plus the in Fig. 10 as an example indicated compounds Tularik (T0901317), LN0000006500, LN0000006662, LN0000006671, LN0000006674 at 10 µM.

**[0121]** After incubation for 24 hours, total cholesterol was determined from cell supernatant in each of the wells using an enzymatic assay with fluorescence read-out for the determination of cholesterol (Amplex Red Cholesterol Assay Kit (A-12213). The fluorescence readout per mg of total protein content as determined from cells that were present in the respective well are shown in Figure 9 as an example.

## SEQUENCE LISTING

5 <110> LION bioscience  
 <120> LXR Nuclear receptor binding compounds  
 <130> FB11712  
 <160> 8  
 <170> PatentIn version 3.1

10 <210> 1  
 <211> 52  
 <212> DNA  
 <213> Homo sapiens

15 <400> 1  
 ggggaccact ttgtacaaga aagctgggtc cccttctcag tctgttccac tt 52

20 <210> 2  
 <211> 1344  
 <212> DNA  
 <213> Homo sapiens

25 <400> 2  
 atgtccttgt ggctgggggc ccctgtgcct gacattcctc ctgactctgc ggtggagctg 60  
 tggaagccag gcgcacagga tgcaagcagc caggcccagg gaggcagcag ctgcatcctc 120  
 agagaggaag ccaggatgcc ccactctgct gggggctactg caggggtggg gctggaggtc 180  
 gcagagccca cagccctgct caccagggca gagccccctt cagaaccac agagatccgt 240  
 ccacaaaagc ggaaaaaggg gccagcccc aaaatgctgg ggaacgagct atgcagcgtg 300  
 30 tgtggggaca aggcctcygg cttccactac aatgttctga gctgcgaggg ctgcaaggga 360  
 ttcttccgcc gcagcgtcat caagggagcg cactacatct gccacagtgg cggccactgc 420  
 cccatggaca cctacatgcg tcgcaagtgc caggagtgtc ggcttcgcaa atgccgtcag 480  
 35 gctggcatgc gggaggagtg tgtcctgtca gaagaacaga tccgcctgaa gaaactgaag 540  
 cggcaagagg aggaacaggc tcatgccaca tccttgcccc ccaggcgctt ctcaccccc 600  
 caaatcctgc ccagctcag ccggaacaa ctgggcatga tcgagaagct cgtcgctgcc 660  
 40 cagcaacagt gtaaccggcg ctccctttct gaccggcttc gagtcacgcc ttggcccatg 720  
 gcaccagatc cccatagccg ggaggccgt cagcagcgt ttgcccactt cactgagctg 780  
 gccatcgtct ctgtgcagga gatagttgac tttgctaaac agctaccgg cttcctgcag 840  
 45 ctcagccggg aggaccagat tgccctgctg aagacctctg cgatcgaggt gatgcttctg 900  
 gagacatctc ggaggtacaa ccctgggagt gagagtatca ccttcctcaa ggatttcagt 960  
 tataaccggg aagactttgc caaagcaggg ctgcaagtgg aattcatcaa cccatcttc 1020  
 50 gagttctcca gggccatgaa tgagctgcaa ctcaatgatg ccgagtttgc cttgctcatt 1080  
 gctatcagca tcttctctgc agaccggccc aacgtgcagg accagctcca ggtggagagg 1140  
 55 ctgcagcaca catatgtgga agccctgcat gcctacgtct ccatccacca tccccatgac 1200



# EP 1 407 774 A1

cgactgatgt tcccacggat gctaataaaa ctggtgagcc tccggaccct gagcagcgtc 1260

5 cactcagagc aagtgtttgc actgcgtctg caggacaaaa agctcccacc gctgctctct 1320

gagatctggg atgtgcacga atga 1344

<210> 3  
 <211> 1263  
 <212> PRT  
 <213> Homo sapiens  
 <400> 3

10 Met Leu Val Lys Pro Leu Pro Asp Ser Glu Glu Glu Gly His Asp Asn  
 1 5 10 15

Gln Glu Ala His Gln Lys Tyr Glu Thr Met Gln Cys Phe Ala Val Ser  
 20 25 30

20 Gln Pro Lys Ser Ile Lys Glu Glu Gly Glu Asp Leu Gln Ser Cys Leu  
 35 40 45

Ile Cys Val Ala Arg Arg Val Pro Met Lys Glu Arg Pro Val Leu Pro  
 25 50 55 60

Ser Ser Glu Ser Phe Thr Thr Arg Gln Asp Leu Gln Gly Lys Ile Thr  
 65 70 75 80

30 Ser Leu Asp Thr Ser Thr Met Arg Ala Ala Met Lys Pro Gly Trp Glu  
 85 90 95

Asp Leu Val Arg Arg Cys Ile Gln Lys Phe His Ala Gln His Glu Gly  
 35 100 105 110

Glu Ser Val Ser Tyr Ala Lys Arg His His His Glu Val Leu Arg Gln  
 115 120 125

40 Gly Leu Ala Phe Ser Gln Ile Tyr Arg Phe Ser Leu Ser Asp Gly Thr  
 130 135 140

Leu Val Ala Ala Gln Thr Lys Ser Lys Leu Ile Arg Ser Gln Thr Thr  
 45 145 150 155 160

Asn Glu Pro Gln Leu Val Ile Ser Leu His Met Leu His Arg Glu Gln  
 165 170 175

50 Asn Val Cys Val Met Asn Pro Asp Leu Thr Gly Gln Thr Met Gly Lys  
 180 185 190

Pro Leu Asn Pro Ile Ser Ser Asn Ser Pro Ala His Gln Ala Leu Cys  
 55 195 200 205

EP 1 407 774 A1

5 Ser Gly Asn Pro Gly Gln Asp Met Thr Leu Ser Ser Asn Ile Asn Phe  
210 215 220

Pro Ile Asn Gly Pro Lys Glu Gln Met Gly Met Pro Met Gly Arg Phe  
225 230 235 240

10 Gly Gly Ser Gly Gly Met Asn His Val Ser Gly Met Gln Ala Thr Thr  
245 250 255

15 Pro Gln Gly Ser Asn Tyr Ala Leu Lys Met Asn Ser Pro Ser Gln Ser  
260 265 270

Ser Pro Gly Met Asn Pro Gly Gln Pro Thr Ser Met Leu Ser Pro Arg  
275 280 285

20 His Arg Met Ser Pro Gly Val Ala Gly Ser Pro Arg Ile Pro Pro Ser  
290 295 300

25 Gln Phe Ser Pro Ala Gly Ser Leu His Ser Pro Val Gly Val Cys Ser  
305 310 315 320

Ser Thr Gly Asn Ser His Ser Tyr Thr Asn Ser Ser Leu Asn Ala Leu  
325 330 335

30 Gln Ala Leu Ser Glu Gly His Gly Val Ser Leu Gly Ser Ser Leu Ala  
340 345 350

35 Ser Pro Asp Leu Lys Met Gly Asn Leu Gln Asn Ser Pro Val Asn Met  
355 360 365

Asn Pro Pro Pro Leu Ser Lys Met Gly Ser Leu Asp Ser Lys Asp Cys  
370 375 380

40 Phe Gly Leu Tyr Gly Glu Pro Ser Glu Gly Thr Thr Gly Gln Ala Glu  
385 390 395 400

45 Ser Ser Cys His Pro Gly Glu Gln Lys Glu Thr Asn Asp Pro Asn Leu  
405 410 415

Pro Pro Ala Val Ser Ser Glu Arg Ala Asp Gly Gln Ser Arg Leu His  
420 425 430

50 Asp Ser Lys Gly Gln Thr Lys Leu Leu Gln Leu Leu Thr Thr Lys Ser  
435 440 445

55 Asp Gln Met Glu Pro Ser Pro Leu Ala Ser Ser Leu Ser Asp Thr Asn

EP 1 407 774 A1

	450		455		460	
5	Lys Asp Ser Thr Gly	Ser Leu Pro Gly	Ser Gly Ser Thr His Gly Thr			
	465	470	475		480	
	Ser Leu Lys Glu Lys His Lys Ile Leu His Arg Leu Leu Gln Asp Ser					
10		485	490		495	
	Ser Ser Pro Val Asp Leu Ala Lys Leu Thr Ala Glu Ala Thr Gly Lys					
		500	505		510	
15	Asp Leu Ser Gln Glu Ser Ser Ser Thr Ala Pro Gly Ser Glu Val Thr					
		515	520		525	
	Ile Lys Gln Glu Pro Val Ser Pro Lys Lys Lys Glu Asn Ala Leu Leu					
20		530	535		540	
	Arg Tyr Leu Leu Asp Lys Asp Asp Thr Lys Asp Ile Gly Leu Pro Glu					
		545	550		555	560
25	Ile Thr Pro Lys Leu Glu Arg Leu Asp Ser Lys Thr Asp Pro Ala Ser					
		565	570		575	
	Asn Thr Lys Leu Ile Ala Met Lys Thr Glu Lys Glu Glu Met Ser Phe					
30		580	585		590	
	Glu Pro Gly Asp Gln Pro Gly Ser Glu Leu Asp Asn Leu Glu Glu Ile					
		595	600		605	
35	Leu Asp Asp Leu Gln Asn Ser Gln Leu Pro Gln Leu Phe Pro Asp Thr					
		610	615		620	
	Arg Pro Gly Ala Pro Ala Gly Ser Val Asp Lys Gln Ala Ile Ile Asn					
40		625	630		635	640
	Asp Leu Met Gln Leu Thr Ala Glu Asn Ser Pro Val Thr Pro Val Gly					
		645	650		655	
45	Ala Gln Lys Thr Ala Leu Arg Ile Ser Gln Ser Thr Phe Asn Asn Pro					
		660	665		670	
	Arg Pro Gly Gln Leu Gly Arg Leu Leu Pro Asn Gln Asn Leu Pro Leu					
50		675	680		685	
	Asp Ile Thr Leu Gln Ser Pro Thr Gly Ala Gly Pro Phe Pro Pro Ile					
		690	695		700	
55						

# EP 1 407 774 A1

Arg Asn Ser Ser Pro Tyr Ser Val Ile Pro Gln Pro Gly Met Met Gly  
 705 710 715 720  
 5  
 Asn Gln Gly Met Ile Gly Asn Gln Gly Asn Leu Gly Asn Ser Ser Thr  
 725 730 735  
 10  
 Gly Met Ile Gly Asn Ser Ala Ser Arg Pro Thr Met Pro Ser Gly Glu  
 740 745 750  
 Trp Ala Pro Gln Ser Ser Ala Val Arg Val Thr Cys Ala Ala Thr Thr  
 755 760 765  
 15  
 Ser Ala Met Asn Arg Pro Val Gln Gly Gly Met Ile Arg Asn Pro Ala  
 770 775 780  
 20  
 Ala Ser Ile Pro Met Arg Pro Ser Ser Gln Pro Gly Gln Arg Gln Thr  
 785 790 795 800  
 Leu Gln Ser Gln Val Met Asn Ile Gly Pro Ser Glu Leu Glu Met Asn  
 805 810 815  
 25  
 Met Gly Gly Pro Gln Tyr Ser Gln Gln Gln Ala Pro Pro Asn Gln Thr  
 820 825 830  
 30  
 Ala Pro Trp Pro Glu Ser Ile Leu Pro Ile Asp Gln Ala Ser Phe Ala  
 835 840 845  
 Ser Gln Asn Arg Gln Pro Phe Gly Ser Ser Pro Asp Asp Leu Leu Cys  
 850 855 860  
 35  
 Pro His Pro Ala Ala Glu Ser Pro Ser Asp Glu Gly Ala Leu Leu Asp  
 865 870 875 880  
 40  
 Gln Leu Tyr Leu Ala Leu Arg Asn Phe Asp Gly Leu Glu Glu Ile Asp  
 885 890 895  
 Arg Ala Leu Gly Ile Pro Glu Leu Val Ser Gln Ser Gln Ala Val Asp  
 900 905 910  
 45  
 Pro Glu Gln Phe Ser Ser Gln Asp Ser Asn Ile Met Leu Glu Gln Lys  
 915 920 925  
 50  
 Ala Pro Val Phe Pro Gln Gln Tyr Ala Ser Gln Ala Gln Met Ala Gln  
 930 935 940  
 Gly Ser Tyr Ser Pro Met Gln Asp Pro Asn Phe His Thr Met Gly Gln  
 945 950 955 960  
 55

# EP 1 407 774 A1

5 Arg Pro Ser Tyr Ala Thr Leu Arg Met Gln Pro Arg Pro Gly Leu Arg  
 965 970 975  
 Pro Thr Gly Leu Val Gln Asn Gln Pro Asn Gln Leu Arg Leu Gln Leu  
 980 985 990  
 10 Gln His Arg Leu Gln Ala Gln Gln Asn Arg Gln Pro Leu Met Asn Gln  
 995 1000 1005  
 15 Ile Ser Asn Val Ser Asn Val Asn Leu Thr Leu Arg Pro Gly Val  
 1010 1015 1020  
 Pro Thr Gln Ala Pro Ile Asn Ala Gln Met Leu Ala Gln Arg Gln  
 1025 1030 1035  
 20 Arg Glu Ile Leu Asn Gln His Leu Arg Gln Arg Gln Met His Gln  
 1040 1045 1050  
 25 Gln Gln Gln Val Gln Gln Arg Thr Leu Met Met Arg Gly Gln Gly  
 1055 1060 1065  
 Leu Asn Met Thr Pro Ser Met Val Ala Pro Ser Gly Met Pro Ala  
 1070 1075 1080  
 30 Thr Met Ser Asn Pro Arg Ile Pro Gln Ala Asn Ala Gln Gln Phe  
 1085 1090 1095  
 35 Pro Phe Pro Pro Asn Tyr Gly Ile Ser Gln Gln Pro Asp Pro Gly  
 1100 1105 1110  
 Phe Thr Gly Ala Thr Thr Pro Gln Ser Pro Leu Met Ser Pro Arg  
 1115 1120 1125  
 40 Met Ala His Thr Gln Ser Pro Met Met Gln Gln Ser Gln Ala Asn  
 1130 1135 1140  
 45 Pro Ala Tyr Gln Ala Pro Ser Asp Ile Asn Gly Trp Ala Gln Gly  
 1145 1150 1155  
 Asn Met Gly Gly Asn Ser Met Phe Ser Gln Gln Ser Pro Pro His  
 1160 1165 1170  
 50 Phe Gly Gln Gln Ala Asn Thr Ser Met Tyr Ser Asn Asn Met Asn  
 1175 1180 1185  
 55 Ile Asn Val Ser Met Ala Thr Asn Thr Gly Gly Met Ser Ser Met  
 1190 1195 1200

# EP 1 407 774 A1

5 Asn Gln Met Thr Gly Gln Ile Ser Met Thr Ser Val Thr Ser Val  
 1205 1210 1215  
  
 Pro Thr Ser Gly Leu Ser Ser Met Gly Pro Glu Gln Val Asn Asp  
 1220 1225 1230  
 10  
 Pro Ala Leu Arg Gly Gly Asn Leu Phe Pro Asn Gln Leu Pro Gly  
 1235 1240 1245  
 15 Met Asp Met Ile Lys Gln Glu Gly Asp Thr Thr Arg Lys Tyr Cys  
 1250 1255 1260  
  
 <210> 4  
 <211> 6158  
 <212> DNA  
 20 <213> Homo sapiens  
  
 <400> 4  
 ggcgcccgca gcctcggcta cagcttcggc ggccaaggct agcgccgacg gcagccggca 60  
 25 cctgacggcg tgaccgaccc gagcggattt ctcttggtt ttgctacaca cttatagatc 120  
 ttctgcaactg ttacaggca cagttgctga tatgtgttca agatgagtg gatgggagaa 180  
 aatacctctg acccctccag ggcagagaca agaaagcgca aggaatgtcc tgaccaactt 240  
 30 ggaccagcc ccaaaaggaa cactgaaaa cgtaatcgtg aacaggaaaa taaatatata 300  
 gaagaacttg cagagttgat ttttgcaaat tttaatgata tagacaactt taacttcaaa 360  
 cctgacaaat gtgcaatctt aaaagaaact gtgaagcaaa ttcgtcagat caaagaacaa 420  
 35 gagaaagcag cagctgcca catagatgaa gtgcagaagt cagatgtatc ctctacaggg 480  
 cagggtgtca tcgacaagga tgcgtgggg cctatgatgc ttgaggccct tgatgggttc 540  
 ttctttgtag tgaacctgga aggcaacgtt gtgtttgtgt cagagaatgt gacacagtat 600  
 40 ctaaggtata accaagaaga gctgatgaac aaaagtgtat atagcatctt gcatgttggg 660  
 gaccacacgg aatttgctaa aaacctgctg ccaagtcta taggtaaatg ggggatcttg 720  
 gtctggcgaa cctccgaggc ggaacagcca taccttcaat tgcggatgc tggtaaaacc 780  
 45 ttacctgat tcagaagagg agggctcatga taaccaggaa gctcatcaga aatatgaaac 840  
 tatgcagtgc ttcgctgtct ctcaacaaaa gtccatcaaa gaagaaggag aagatttgca 900  
 gtcctgcttg atttgcgtgg caagaagagt tcccatgaag gaaagaccag ttcttccctc 960  
 50 atcagaaaagt ttactactc gccaggatct ccaaggcaag atcacgtctc tggataccag 1020  
 caccatgaga gcagccatga aaccaggctg ggaggacctg gtaagaagggt gtattcagaa 1080  
 gttccatgcg cagcatgaag gagaatctgt gtcctatgct aagaggcatc atcatgaagt 1140  
 55 actgagacaa ggattggcat tcagtcaaat ctatcgtttt tccttgtctg atggcactct 1200

# EP 1 407 774 A1

	tgttgctgca	caaacgaaga	gcaaactcat	ccgttctcag	actactaatg	aacctcaact	1260
5	tgtaatatct	ttacatatgc	ttcacagaga	gcagaatgtg	tgtgtgatga	atccggatct	1320
	gactggacaa	acgatgggga	agccactgaa	tccaattagc	tctaacagcc	ctgcccacatca	1380
	ggccctgtgc	agtgggaacc	caggtcagga	catgaccctc	agtagcaata	taaatTTTTcc	1440
10	cataaatggc	caaaggaac	aatgggcat	gcccatgggc	aggtttgggtg	gttctggggg	1500
	aatgaacccat	gtgtcaggca	tgcaagcaac	cactcctcag	ggtagtaact	atgcactcaa	1560
	aatgaacagc	ccctcacaaa	gcagccctgg	catgaatcca	ggacagccca	cctccatgct	1620
15	ttcaccaagg	catcgcatga	gccctggagt	ggctggcagc	cctcgaatcc	caccagtc	1680
	gttttccct	gcaggaagct	tgcatcccc	tgtgggagtt	tgacagagca	caggaaatag	1740
	ccatagttat	accaacagct	ccctcaatgc	acttcaggcc	ctcagcgagg	ggcacgggggt	1800
20	ctcattaggg	tcatcgttgg	cttcaccaga	cctaaaaatg	ggcaatttgc	aaaactcccc	1860
	agttaatatg	aatcctcccc	cactcagcaa	gatgggaagc	ttggactcaa	aagactgttt	1920
	tggactatat	ggggagccct	ctgaaggta	aactggacaa	gcagagagca	gctgccatcc	1980
25	tggagagcaa	aaggaaacaa	atgaccccaa	cctgcccccg	gccgtgagca	gtgagagagc	2040
	tgacgggcag	agcagactgc	atgacagcaa	agggcagacc	aaactcctgc	agctgctgac	2100
	caccaaactct	gatcagatgg	agccctcgcc	cttagccagc	tctttgtcgg	atacaaaacaa	2160
30	agactccaca	ggtagcttgc	ctggttctgg	gtctacacat	ggaacctcgc	tcaaggagaa	2220
	gcataaaatt	ttgcacagac	tcttgacagga	cagcagttcc	cctgtggact	tggccaagtt	2280
	aacagcagaa	gccacaggca	aagacctgag	ccaggagtcc	agcagcacag	ctcctggatc	2340
35	agaagtgact	attaacaag	agccggtgag	ccccagaag	aaagagaatg	cactacttcg	2400
	ctatttgcta	gataaagatg	atactaaaga	tattggttta	ccagaaataa	cccccaaact	2460
	tgagagactg	gacagtaaga	cagatcctgc	cagtaacaca	aaattaatag	caatgaaaac	2520
40	tgagaaggag	gagatgagct	ttgagcctgg	tgaccagcct	ggcagtgagc	tggacaactt	2580
	ggaggagatt	ttggatgatt	tgacagaatag	tcaattacca	cagcttttcc	cagacacgag	2640
	gccaggcgcc	cctgctggat	cagttgacaa	gcaagccatc	atcaatgacc	tcatgcaact	2700
45	cacagctgaa	aacagccctg	tcacacctgt	tggagcccag	aaaacagcac	tgcgaaatttc	2760
	acagagcact	tttaataacc	cacgaccagg	gcaactgggc	aggttattgc	caaaccagaa	2820
	tttaccactt	gacatcacat	tgcaaagccc	aactggtgct	ggacctttcc	caccaatcag	2880
50	aaacagtagt	ccctactcag	tgatacctca	gccaggaatg	atgggtaatc	aagggatgat	2940
	aggaaaccaa	ggaaatttag	ggaacagtag	cacaggaatg	attggttaaca	gtgcttctcg	3000
	gcctactatg	ccatctggag	aatgggcacc	gcagagttcg	gctgtgagag	tcacctgtgc	3060
55							

EP 1 407 774 A1

	tgctaccacc agtgccatga accggccagt ccaaggaggt atgattcgga acccagcagc	3120
5	cagcatcccc atgaggccca gcagccagcc tggccaaaga cagacgcttc agtctcaggt	3180
	catgaatata gggccatctg aattagagat gaacatgggg ggacctcagt atagccaaca	3240
	acaagctcct ccaaatacaga ctgccccatg gcctgaaagc atcctgccta tagaccaggc	3300
10	gtcttttgcc agccaaaaca ggcagccatt tggcagttct ccagatgact tgctatgtcc	3360
	acatcctgca gctgagtctc cgagtgatga gggagctctc ctggaccagc tgtatctggc	3420
	cttgcggaat tttgatggcc tggaggagat tgatagagcc ttaggaatac ccgaactggg	3480
15	cagccagagc caagcagtag atccagaaca gttctcaagt caggattcca acatcatgct	3540
	ggagcagaag gcgcccgttt tcccacagca gtatgcatct caggcacaaa tggcccaggg	3600
	tagctattct cccatgcaag atccaaactt tcacaccatg ggacagcggc ctagttagtc	3660
20	cacactcogt atgcajccca gaccgggcct caggcccacg ggcctagtgc agaaccagcc	3720
	aatcaacta agacttcaac ttcagcatcg cctccaagca cagcagaatc gccagccact	3780
	tatgaatcaa atcagcaatg tttccaatgt gaacttgact ctgaggcctg gagtaccaac	3840
25	acaggcacct attaatgcac agatgctggc ccagagacag agggaaatcc tgaaccagca	3900
	tcttcgacag agacaaatgc atcagcaaca gcaagttcag caacgaactt tgatgatgag	3960
	aggacaaggg ttgaatatga caccaagcat ggtggctcct agtggtatgc cagcaactat	4020
30	gagcaaccct cggattcccc aggcaaagtc acagcagttt ccatttctc caaactacgg	4080
	aataagtcag caacctgatc caggctttac tggggctacg actccccaga gccacttat	4140
	gtcaccgccga atggcacata cacagagtcc catgatgcaa cagtctcagg ccaaccagc	4200
35	ctatcaggcc ccctccgaca taaatggatg ggcgagggg aacatgggag gaaacagcat	4260
	gttttcccag cagtccccac cacacttttg gcagcaagca aacaccagca tgtacagtaa	4320
	caacatgaac atcaatgtgt ccatggcgac caacacaggt ggcatgagca gcatgaacca	4380
40	gatgacagga cagatcagca tgacctcagt gacctccgtg cctacgtcag ggctgtcctc	4440
	catgggtccc gagcaggtta atgatcctgc tctgagggga ggcaacctgt tcccaaacca	4500
	gctgcctgga atggatatga ttaagcagga gggagacaca acacggaaat attgctgaca	4560
45	ctgctgaagc cagttgcttc ttcagctgac cgggctcact tgctcaaac acttcagtc	4620
	tggagagctg tgtctatttg tttcaaccca actgacctgc cagccggttc tgctagagca	4680
	gacaggcctg gccctggttc ccagggtggc gtccactcgg ctgtggcagg aggagctgcc	4740
50	tcttctcttg acagtctgaa gctcgcaccc agacagtcgc tcagtctgtt cactgcattc	4800
	accttagtgc aacttagatc tctcctgcaa aagtaaatgt tgacaggcaa atttcatacc	4860
	catgtcagat tgaatgtatt taaatgtatg tatttaagga gaacctagct cttgttctgt	4920
55	tcctgttcgg ttccagacac tgggttcttg ctttgttttc cctggctaac agtctagtgc	4980



# EP 1 407 774 A1

5  
 10  
 15  
 20  
 25  
 30  
 35

aaaagattaa gattttatct gggggaaaga aaagaatttt ttaaaaaatt aaactaaaga 5040  
 tgttttaagc taaagcctga atttgggatg gaagcaggac agacaccgtg gacagcgctg 5100  
 tatttacaga cacaccagc gcgtgaagac caacaaagtc acagtcgtat ctctagaaaag 5160  
 ctctaaagac catgttggaag agagtctcca gttactgaac agatgaaaag gagcctgtga 5220  
 gagggctgtt aacattagca aatatttttt ccttggtttt tctttgttaa aaccaaaactg 5280  
 gttcacctga atcatgaatt gagaagaaat aattttcatt tctaaattaa gtccctttta 5340  
 gtttgatcag acagcttgaa tcagcatctc ttcttccctg tcagcctgac tcttcccttc 5400  
 ccctctctca ttcccatac tccctatttt cattcctttt ttaaaaaata atataagcta 5460  
 cagaaaccag gtaagccctt ttttccctta aatgttttgc cagccactta ccaattgcta 5520  
 agtattgaat ttcagaaaaa aaaaatgcat ttactggcaa ggagaagagc aaagttaagg 5580  
 cttgatacca atcgagctaa ggatacctgc tttggaagca tgtttattct gttcccagc 5640  
 aactctggcc tccaaaatgg gagaaaacgc cagtgtgttt aaattgatag cagatatcac 5700  
 gacagattta acctctgcca tgtgtttttt attttgtttt ttagcagtgc tgactaagcc 5760  
 gaagtgttgt aaggtagata aaatccaatt tatatgtaaa caagcaataa ttaagtgtga 5820  
 gaacttatgt gttttaattg tataattttt gtgaggtata catattgtgg aattgactca 5880  
 aaaatgaggt acttcagtat taaattagat atcttcatag caatgtctcc taaaggtgtt 5940  
 ttgtaaagga tatcaatgcc ttgattagac ctaatttgta gacttaagac tttttatttt 6000  
 ctaaaccctg tgattctgct tataagtcat ttatctaate tatatgatat gcagccgctg 6060  
 taggaaccaa ttcttgattt ttatatgttt atattctttc ttaatgaacc ttagaaagac 6120  
 tacatgttac taagcaggcc acttttatgg ttgttttt 6158

40  
 45

<210> 5  
 <211> 460  
 <212> PRT  
 <213> Homo sapiens  
 <400> 5

45  
 50  
 55

Met Ser Ser Pro Thr Thr Ser Ser Leu Asp Thr Pro Leu Pro Gly Asn  
 1 5 10 15  
 Gly Pro Pro Gln Pro Gly Ala Pro Ser Ser Ser Pro Thr Val Lys Glu  
 20 25 30  
 Glu Gly Pro Glu Pro Trp Pro Gly Gly Pro Asp Pro Asp Val Pro Gly  
 35 40 45  
 Thr Asp Glu Ala Ser Ser Ala Cys Ser Thr Asp Trp Val Ile Pro Asp  
 50 55 60

EP 1 407 774 A1

5	Pro Glu Glu Glu Pro Glu Arg Lys Arg Lys Lys Gly Pro Ala Pro Lys	65	70	75	80
	Met Leu Gly His Glu Leu Cys Arg Val Cys Gly Asp Lys Ala Ser Gly	85	90	95	
10	Phe His Tyr Asn Val Leu Ser Cys Glu Gly Cys Lys Gly Phe Phe Arg	100	105	110	
15	Arg Ser Val Val Arg Gly Gly Ala Arg Arg Tyr Ala Cys Arg Gly Gly	115	120	125	
	Gly Thr Cys Gln Met Asp Ala Phe Met Arg Arg Lys Cys Gln Gln Cys	130	135	140	
20	Arg Leu Arg Lys Cys Lys Glu Ala Gly Met Arg Glu Gln Cys Val Leu	145	150	155	160
25	Ser Glu Glu Gln Ile Arg Lys Lys Lys Ile Arg Lys Gln Gln Gln Glu	165	170	175	
	Ser Gln Ser Gln Ser Gln Ser Pro Val Gly Pro Gln Gly Ser Ser Ser	180	185	190	
30	Ser Ala Ser Gly Pro Gly Ala Ser Pro Gly Gly Ser Glu Ala Gly Ser	195	200	205	
35	Gln Gly Ser Gly Glu Gly Glu Gly Val Gln Leu Thr Ala Ala Gln Glu	210	215	220	
	Leu Met Ile Gln Gln Leu Val Ala Ala Gln Leu Gln Cys Asn Lys Arg	225	230	235	240
40	Ser Phe Ser Asp Gln Pro Lys Val Thr Pro Trp Pro Leu Gly Ala Asp	245	250	255	
45	Pro Gln Ser Arg Asp Ala Arg Gln Gln Arg Phe Ala His Phe Thr Glu	260	265	270	
	Leu Ala Ile Ile Ser Val Gln Glu Ile Val Asp Phe Ala Lys Gln Val	275	280	285	
50	Pro Gly Phe Leu Gln Leu Gly Arg Glu Asp Gln Ile Ala Leu Leu Lys	290	295	300	
55	Ala Ser Thr Ile Glu Ile Met Leu Leu Glu Thr Ala Arg Arg Tyr Asn	305	310	315	320

# EP 1 407 774 A1

5 His Glu Thr Glu Cys Ile Thr Phe Leu Lys Asp Phe Thr Tyr Ser Lys  
 325 330 335  
 Asp Asp Phe His Arg Ala Gly Leu Gln Val Glu Phe Ile Asn Pro Ile  
 340 345 350  
 10 Phe Glu Phe Ser Arg Ala Met Arg Arg Leu Gly Leu Asp Asp Ala Glu  
 355 360 365  
 15 Tyr Ala Leu Leu Ile Ala Ile Asn Ile Phe Ser Ala Asp Arg Pro Asn  
 370 375 380  
 Val Gln Glu Pro Gly Arg Val Glu Ala Leu Gln Gln Pro Tyr Val Glu  
 385 390 395 400  
 20 Ala Leu Leu Ser Tyr Thr Arg Ile Lys Arg Pro Gln Asp Gln Leu Arg  
 405 410 415  
 25 Phe Pro Arg Met Leu Met Lys Leu Val Ser Leu Arg Thr Leu Ser Ser  
 420 425 430  
 Val His Ser Glu Gln Val Phe Ala Leu Arg Leu Gln Asp Lys Lys Leu  
 435 440 445  
 30 Pro Pro Leu Leu Ser Glu Ile Trp Asp Val His Glu  
 450 455 460  
 35 <210> 6  
 <211> 1383  
 <212> DNA  
 <213> Homo sapiens  
 <400> 6  
 atgtcctctc ctaccacgag ttccctggat acccccctgc ctggaaatgg cccccctcag 60  
 40 cctggcgcc cttcttcttc acccactgta aaggaggagg gtccggagcc gtggcccggg 120  
 ggtccggacc ctgatgtccc aggcactgat gaggccagct cagcctgcag cacagactgg 180  
 gtcacccag atcccgaaga ggaaccagag cgcaagcgaa agaagggcc agccccgaag 240  
 45 atgctgggccc acgagctttg ccgtgtctgt ggggacaagg cctccggctt ccactacaac 300  
 gtgctcagct gcgaaggctg caagggttc ttccggcgca gtgtggtccg tgggtggggcc 360  
 aggcgctatg cctgccgggg tggcggaacc tgccagatgg acgctttcat gcggcgcaag 420  
 50 tgccagcagt gccggtgcg caagtgaag gaggcaggga tgaggagca gtgcgtcctt 480  
 tetgaagaac agatccggaa gaagaagatt cggaacagc agcaggagtc acagtcacag 540  
 tcgcagtcac ctgtggggcc gcagggcagc agcagctcag cctctgggccc tggggcttcc 600  
 55

# EP 1 407 774 A1

cctggtggat ctgaggcagg cagccagggc tccggggaag gcgagggtgt ccagctaaca 660  
 5 gcggtcctcaag aactaatgat ccagcagttg gtggcgggccc aactgcagtg caacaaacgc 720  
 tccttctccg accagcccaa agtcacgccc tggccctgg gcgcagaccc ccagtcccga 780  
 gatgcccgcc agcaacgctt tgcccacttc acggagctgg ccatcatctc agtcaggag 840  
 10 atcgtggact tcgctaagca agtgctggt ttctgcagc tgggcccggga ggaccagatc 900  
 gccctcctga aggcattccac tatcgagatc atgctgctag agacagccag gcgctacaac 960  
 cactgagacag agtgtatcac cttcttgaag gacttcacct acagcaagga cgacttccac 1020  
 15 cgtgcaggcc tgcaggtgga gttcatcaac cccatcttcg agttctcgcg ggccatgcgg 1080  
 cggttgggccc tggacgacgc tgagtacgcc ctgctcatcg ccatcaacat cttctcggcc 1140  
 gaccggccca acgtgcagga gccggggccgc gtggaggcgt tgcagcagcc ctacgtggag 1200  
 20 gcgctgctgt cctacacgcg catcaagagg ccgcaggacc agctgcgctt cccgcgcagt 1260  
 ctcatgaagc tgggtgagcct gcgcacgctg agctctgtgc actcggagca ggtcttcgcc 1320  
 ttgcggctcc aggacaagaa gctgccgcct ctgctgtcgg agatctggga cgtccacgag 1380  
 25 tga 1383

<210> 7  
 <211> 49  
 <212> DNA  
 30 <213> Homo sapiens  
 <400> 7  
 ggggacaagt ttgtacaaaa aagcaggctc gcttcgcaaa tgccgtcag 49

35 <210> 8  
 <211> 447  
 <212> PRT  
 <213> Homo sapiens  
 <400> 8

40 Met Ser Leu Trp Leu Gly Ala Pro Val Pro Asp Ile Pro Pro Asp Ser  
 1 5 10 15

45 Ala Val Glu Leu Trp Lys Pro Gly Ala Gln Asp Ala Ser Ser Gln Ala  
 20 25 30

Gln Gly Gly Ser Ser Cys Ile Leu Arg Glu Glu Ala Arg Met Pro His  
 35 40 45

50 Ser Ala Gly Gly Thr Ala Gly Val Gly Leu Glu Ala Ala Glu Pro Thr  
 50 55 60

55 Ala Leu Leu Thr Arg Ala Glu Pro Pro Ser Glu Pro Thr Glu Ile Arg  
 65 70 75 80

EP 1 407 774 A1


5 Pro Gln Lys Arg Lys Lys Gly Pro Ala Pro Lys Met Leu Gly Asn Glu  
 85 90 95  
 Leu Cys Ser Val Cys Gly Asp Lys Ala Ser Gly Phe His Tyr Asn Val  
 100 105 110  
 10 Leu Ser Cys Glu Gly Cys Lys Gly Phe Phe Arg Arg Ser Val Ile Lys  
 115 120 125  
 Gly Ala His Tyr Ile Cys His Ser Gly Gly His Cys Pro Met Asp Thr  
 15 130 135 140  
 Tyr Met Arg Arg Lys Cys Gln Glu Cys Arg Leu Arg Lys Cys Arg Gln  
 145 150 155 160  
 20 Ala Gly Met Arg Glu Glu Cys Val Leu Ser Glu Glu Gln Ile Arg Leu  
 165 170 175  
 Lys Lys Leu Lys Arg Gln Glu Glu Glu Gln Ala His Ala Thr Ser Leu  
 25 180 185 190  
 Pro Pro Arg Arg Ser Ser Pro Pro Gln Ile Leu Pro Gln Leu Ser Pro  
 195 200 205  
 30 Glu Gln Leu Gly Met Ile Glu Lys Leu Val Ala Ala Gln Gln Gln Cys  
 210 215 220  
 Asn Arg Arg Ser Phe Ser Asp Arg Leu Arg Val Thr Pro Trp Pro Met  
 35 225 230 235 240  
 Ala Pro Asp Pro His Ser Arg Glu Ala Arg Gln Gln Arg Phe Ala His  
 245 250 255  
 40 Phe Thr Glu Leu Ala Ile Val Ser Val Gln Glu Ile Val Asp Phe Ala  
 260 265 270  
 Lys Gln Leu Pro Gly Phe Leu Gln Leu Ser Arg Glu Asp Gln Ile Ala  
 45 275 280 285  
 Leu Leu Lys Thr Ser Ala Ile Glu Val Met Leu Leu Glu Thr Ser Arg  
 290 295 300  
 50 Arg Tyr Asn Pro Gly Ser Glu Ser Ile Thr Phe Leu Lys Asp Phe Ser  
 305 310 315 320  
 Tyr Asn Arg Glu Asp Phe Ala Lys Ala Gly Leu Gln Val Glu Phe Ile  
 55 325 330 335

# EP 1 407 774 A1

5 Asn Pro Ile Phe Glu Phe Ser Arg Ala Met Asn Glu Leu Gln Leu Asn  
 340 345 350  
 Asp Ala Glu Phe Ala Leu Leu Ile Ala Ile Ser Ile Phe Ser Ala Asp  
 355 360 365  
 10 Arg Pro Asn Val Gln Asp Gln Leu Gln Val Glu Arg Leu Gln His Thr  
 370 375 380  
 15 Tyr Val Glu Ala Leu His Ala Tyr Val Ser Ile His His Pro His Asp  
 385 390 395 400  
 Arg Leu Met Phe Pro Arg Met Leu Met Lys Leu Val Ser Leu Arg Thr  
 405 410 415  
 20 Leu Ser Ser Val His Ser Glu Gln Val Phe Ala Leu Arg Leu Gln Asp  
 420 425 430  
 25 Lys Lys Leu Pro Pro Leu Leu Ser Glu Ile Trp Asp Val His Glu  
 435 440 445  
 30  
 35  
 40  
 45  
 50  
 55

## Claims


1. A compound of the formula (1), or pharmaceutical acceptable salts or solvates thereof according to formula (1)



wherein:

$R_1$ ,  $R_2$ ,  $R_3$  and/or  $R_4$ , is independently from each other H, halogen, hydroxy, protected hydroxy, cyano, nitro,  $C_1$  to  $C_6$  alkyl,  $C_1$  to  $C_6$  substituted alkyl,  $C_1$  to  $C_7$  alkoxy,  $C_1$  to  $C_7$  substituted alkoxy,  $C_1$  to  $C_7$  acyl,  $C_1$  to  $C_7$  substituted acyl,  $C_1$  to  $C_7$  acyloxy, carboxy, protected carboxy, carboxymethyl, protected carboxymethyl, hydroxymethyl, protected hydroxymethyl, amino, protected amino, (monosubstituted)amino, protected (monosubstituted)amino, (disubstituted)amino, carboxamide, protected carboxamide, N-( $C_1$  to  $C_6$  alkyl)carboxamide, protected N-( $C_1$  to  $C_6$  alkyl)carboxamide, N, N-di( $C_1$  to  $C_6$  alkyl)carboxamide, trifluoromethyl, N-(( $C_1$  to  $C_6$  alkyl)sulfonyl)amino, N-(phenylsulfonyl)amino or phenyl, wherein the phenyl is substituted or unsubstituted,  $R_5$  is H,  $C_1$  to  $C_8$  alkyl,  $C_1$  to  $C_8$  substituted alkyl,  $C_7$  to  $C_{12}$  alkylphenyl or  $C_7$  to  $C_{12}$  substituted phenylalkyl,  $R_6$  is H,  $C_1$  to  $C_8$  alkyl,  $C_1$  to  $C_8$  substituted alkyl,  $C_7$  to  $C_{12}$  alkylphenyl or  $C_7$  to  $C_{12}$  substituted phenylalkyl, and  $R_7$  is H,  $C_1$  to  $C_8$  alkyl,  $C_1$  to  $C_8$  substituted alkyl,  $C_7$  to  $C_{12}$  alkylphenyl or  $C_7$  to  $C_{12}$  substituted phenylalkyl.


2. A compound according to claim 1 wherein  $R_6$  and  $R_7$  are taken together with nitrogen to form a heterocycle or substituted heterocycle or a heteroaryl or substituted heteroaryl according to the following formula (2).



3. A compound according to claim 2, or pharmaceutical acceptable salts or solvates thereof, wherein:


$R_1$ ,  $R_2$ ,  $R_3$ ,  $R_4$ , is H, halogen, hydroxy, protected hydroxy, cyano, nitro,  $C_1$  to  $C_6$  alkyl,  $C_1$  to  $C_6$  substituted alkyl,  $C_1$  to  $C_7$  alkoxy,  $C_1$  to  $C_7$  substituted alkoxy,  $C_1$  to  $C_7$  acyl,  $C_1$  to  $C_7$  substituted acyl,  $C_1$  to  $C_7$  acyloxy, carboxy, protected carboxy, carboxymethyl, protected carboxymethyl, hydroxymethyl, protected hydroxymethyl, amino, protected amino, (monosubstituted)amino, protected (monosubstituted)amino, (disubstituted)amino, carboxamide, protected carboxamide, N-( $C_1$  to  $C_6$  alkyl)carboxamide, protected N-( $C_1$  to  $C_6$  alkyl)carboxamide, N, N-di( $C_1$  to  $C_6$  alkyl)carboxamide, trifluoromethyl, N-(( $C_1$  to  $C_6$  alkyl)sulfonyl)amino, N-(phenylsulfonyl)amino or phenyl, and  $R_5$  is H,  $C_1$  to  $C_8$  alkyl,  $C_1$  to  $C_8$  substituted alkyl.

4. A compound according to claim 1 wherein  $R_6$  and  $R_7$  are taken together with nitrogen to form the heterocycle according to the following formula (3)




5. A compound according to any of claims 1 to 3 of the following formula (4)

formula (4)




6. A compound according to any of claims 1 to 3 of the following formula (5)

formula (5)



7. A compound according to any of claims 1 to 3 of the following formula (6)


formula (6)



8. A compound according to any of claims 1 and 4 wherein  $R_6$  and  $R_7$  are taken together with nitrogen to form the heterocycle according to the following formula (7)




formula (7)




9. A compound according to claim 1 according to the following formula (8)

formula (8)



10. A compound according to claims 1 and 4 according to the following formula (8)

formula (8)



11. A compound according to any of claims 1 to 10 wherein said compound is capable of binding the NR1H3 receptor protein or a portion thereof according to SEQ ID NO. 1 or a mammalian homologue thereof.

12. A compound according to any of claims 1 to 10 wherein said compound is capable of binding the NR1H2 receptor protein or a portion thereof or a mammalian homologue thereof.

13. Use of a compound according to any of claims 1 to 12 as a medicament

14. A method for prevention or treatment of a NR1H3 and/or NR1H2 receptor protein mediated disease or NR1H3 and/or NR1H2 receptor protein homologue mediated disease or condition in a mammal comprising administering a therapeutically effective amount of a compound according to any of claims 1 to 12, wherein the prevention or treatment is directly or indirectly accomplished through the binding of the compound according to claims 1 to 13 to

the NR1H3 and/or NR1H2 receptor proteins or to the NR1H3 and/or NR1H2 receptor protein homologues.

15. A method for prevention or treatment of a NR1H3 receptor protein and/or NR1H2 receptor protein mediated disease or condition according to claim 14, wherein said mammal is a human.

16. A method for regulating the cholesterol synthesis and/or transport in a mammal which comprises activating the NR1H3 and/or NR1H2 receptors with a therapeutically effective amount of a compound according to claims 1 to 12.

17. A method of treating in a mammal a disease which is affected by cholesterol, triglyceride, or bile acid levels comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound according to claims 1 to 12.

18. A method of treating atherosclerosis, alzheimers disease, lipid disorders, obesity or a cardiovascular disorder in a mammal, in particular a human, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound according to claims 1 to 12.

19. A method according to any of claims 14 to 18 wherein the expression of ABCA 1 and/or ABCG1 and/or ABCG5 and/or ABCG8 is increased.

20. A method according to any of claims claim 14 to 19 wherein the expression of the cholesterol 7  $\alpha$  hydroxylase and/or the activity of the cholesteryl ester transfer protein is increased.

21. A method of blocking in a mammal the cholesterol or fatty acid absorption in the intestine of a mammal in need of such blocking comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound according to claims 1 to 12.

22. A method for treating obesity in a mammal comprising administering a therapeutically effective amount of a compound according to any of claims 1 to 12.

23. A method of modulating a gene whose expression is regulated by the NR1H3 and/or NR1H2 receptor in a mammal comprising administering a therapeutically effective amount of a compound according to claims 1 to 10.

24. A method according to any of claims claim 14 to 19 wherein the expression of the cholesterol 7  $\alpha$  hydroxylase and/or the activity of the cholesteryl ester transfer protein is enhanced.

25. Use of a compound according to any of claims 1 to 12 wherein the mammal is a human

26. Use of a compound according to any of claims 1 to 12 for the manufacture of a medicament for the prevention or treatment of a NR1H3 and/or NR1H2 receptor protein or NR1H3 and/or NR1H2 receptor protein homologue mediated disease or condition in a mammal wherein the prevention or treatment is directly or indirectly accomplished through the binding of the compound according claims 1 to 8 to the NR1H3 and/or NR1H2 receptor protein or NR1H3 and/or NR1H2 receptor protein homologue.

27. Use of a compound according to any of claims 1 to 12 for the manufacture of a medicament for prevention or treatment of a NR1H3 and/or NR1H2 receptor protein mediated disease or condition according to claim 26, wherein the mammal is a human.

28. Use of a compound according to any of claims 1 to 12 for the manufacture of a medicament for regulating the cholesterol transport system in a mammal by activating the NR1H3 and/or NR1H2 receptor.

29. Use of a compound according to any of claims 1 to 12 for the manufacture of a medicament for regulating levels of cholesterol, triglyceride, and/or bile acid.

30. Use of a compound according to any of claims 1 to 12 for the manufacture of a medicament for treating in a mammal atherosclerosis, alzheimer disease, gallstone disease, lipid disorders, obesity or a cardiovascular disorder.

31. Use of a compound according to any of claims 1 to 12 for the manufacture of a medicament capable for blocking in a mammal the cholesterol and/or fatty acid absorption in the intestine.


**32.** Use of the compound according to any of claims 1 to 12 for the manufacture of a medicament for treating obesity in a mammal.

**33.** Use of a compound according to any of claims 1 to 12 for the manufacture of a medicament for modulating a gene whose expression is regulated by the NR1H3 and/or NR1H2 receptor.

**34.** Use of a compound according to any of claims 1 to 12 in a mammal for the selective up-regulation of one or more genes selected from the group consisting of ABCA1, ABCG1, ABCG5 and ABCG8 and a down-regulation of one or more of the genes selected from the group comprising FAS and SREBP-1c, said compound showing a larger difference in regulation of the two groups of genes when compared with the regulatory behavior of T0901317 on both groups of genes.

**35.** Use of a compound according to claims 28, 30, 31, 32, and 34 wherein the mammal is a human.

**Fig. 1:**



**Fig. 2 : Measurement parameters employed by the Wallace VICTOR2V™ Multilabel Counter:**

Number of repeats .....	1
plate: GREINER FIA-Plate black 384 well med. binding	
Measurement height .....	3.50 mm
Label technology .....	TR-F Lance
Emission filter name .....	D615
Emission filter slot .....	A1
Emission aperture .....	Normal
Excitation filter .....	D340
Delay .....	50 $\mu$ s
Window time .....	400 $\mu$ s
Cycle .....	1000 $\mu$ s
Light integrator capacitors .....	1
Light integrator ref. level .....	95
Flash energy area .....	High
Flash energy level .....	223
Flash absorbance measurement .....	No
Beam .....	Normal
Label technology .....	TR-F Lance
Emission filter name .....	D665
Emission filter slot .....	A8
Emission aperture .....	Normal
Excitation filter .....	D340
Delay .....	50 $\mu$ s
Window time .....	400 $\mu$ s
Cycle .....	1000 $\mu$ s
Light integrator capacitors .....	1
Light integrator ref. level .....	95
Flash energy area .....	High
Flash energy level .....	223
Flash absorbance measurement .....	No
Beam .....	Normal

**Fig. 3 A and B:****A**

```

1 mslwlgapvp dipldsavel wkpgaqdass qaaggsscil reearmphsa ggtagvglea
61 aeptalltra eppsepteir pqkrkkgpap kmlgnelcsv cgdkasgfhy nvlsccegckg
121 ffrsvikga hyichsgghc pmdtymrrkc qecrlrkcrq agmreecvls eeqirlkklk
181 rqeegqahat slpprrsspp qilpqlspeq lgmieklvaa qqcnrrsfs dlrvtwpwpm
241 apdphsrear qqrfahtel aivsvqeivd fakqlpgflq lsredqiall ktsaievml
301 etsrrynpgs esitflkdfs ynredfakag lqvefinpif efsramnelq lndaefalli
361 aisifsadrp nvqdlqver lqhtyvealh ayvsihhphd rlmfprmlmk lvsirtlssv
421 hseqvfalrl qdkklppls eiwdvhe

```

**B**

```

1 atgtccttgt ggctgggggc ccctgtgcct gacattcctc ctgactctgc ggtggagctg
61 tggaagccag gcgcacagga tgcaagcagc caggcccagg gaggcagcag ctgcatcctc
121 agagaggaag ccaggatgcc ccactctgct gggggtactg cagggggtgg gctggaggct
181 gcagagccca cagccctgct caccagggca gagccccctt cagaaccacac agagatccgt
241 ccacaaaagc ggaaaaaggg gccagcccc aaatgtctgg ggaacgagct atgcagcgtg
301 tgtggggaca aggcctcggg cttccactac aatgttctga gctgcgaggg ctgcaaggga
361 ttcttccgcc gcagcgtcat caaggagcgc cactacatct gccacagtgg cggccactgc
421 cccatggaca cctacatgcg tcgcaagtgc caggagtgtc ggcttcgcaa atgccgtcag
481 gctggcatgc gggaggagtg tgtcctgtca gaagaacaga tccgcctgaa gaaactgaag
541 cggcaagagg aggaacaggc tcatgccaca tccttgcccc ccaggcgttc ctcaccccc
601 caaatcctgc cccagctcag cccggaacaa ctgggcatga tcgagaagct cgtcgctgcc
661 cagcaacagt gtaaccggcg ctccttttct gaccggcttc gagtacgcc ttggcccatg
721 gcaccagatc cccatagccg ggaggcccg cagcagcgt ttgcccactt cactgagctg
781 gccatcgtct ctgtgcagga gatagttgac tttgctaaac agctaccggg cttcctgcag
841 ctgagccggg aggaccagat tgccctgctg aagacctctg cgatcgaggt gatgcttctg
901 gagacatctc ggaggtacaa ccctgggagt gagagtatca ccttctctaa ggatttcaat
961 tataaccggg aagactttgc caaagcaggg ctgcaagtgg aattcatcaa cccatcttc
1021 gatttctcca gggccatgaa tgagctgcaa ctcaatgatg ccgagtttgc cttgctcatt
1081 gctatcagca tcttctctgc agaccggccc aacgtgcagg accagctcca ggtggagagg
1141 ctgcagcaca catatgtgga agccctgcat gcctacgtct ccatccacca tccccatgac
1201 cgactgatgt tcccacggat gctaataaaa ctggtgagcc tccggaccct gagcagcgtc
1261 cactcagagc aagtgtttgc actgcgtctg caggacaaaa agctcccacc gctgctctct
1321 gagatctggg atgtgcacga atga

```

1431

Fig. 3 C and D:

C

MLVKPLPDSE	EEGHDNQEAH	QKYETMQCFA	VSQPKSIEKE	GEDLQSCLIC	VARRVPMKER	60
PVLPSSSESFT	TRQDLQGGKIT	SLDTSTMRAA	MKPGWEDLVR	RCIQKFHAQH	EGESVSIAKR	120
HHHEVLROGL	AFSQIYRFSL	SDGTLVAAQT	KSKLIRSQTT	NEPQLVISLH	MLHREQNVCV	180
MNPDLTGQTM	GKPLNPISSN	SPAHAQALCSG	NPGQDMTLSS	NINFINGPK	EQMGMPMGRF	240
GGSGGMNHVS	GMQATTPOGS	NYALKMNSPS	QSSPGMNPQ	PTSMLSPRHR	MSPGVAGSFR	300
IPPSQFSPAG	SLHSPVGVCS	STGNSSHSTN	SSLNALQALS	EGHGVSLGSS	LASPDLMGN	360
LQNSPVNMNP	PPLSKMGSLD	SKDCFLGYGE	PSEGTGQAE	SSCHPGEQKE	TNDPNLPPAV	420
SSERADGQSR	LHDSKGQTKL	LQLLTKSDQ	MEPSPLASSL	SDTNKSTGS	LPGSGSTHGT	480
SLKEKHILH	RLQDSSSPV	DLAKLTAEAT	GKDLSEQESS	TAPGSEVTIK	QEPVSPKKKE	540
NALLRYLLDK	DDTKDIGLPE	ITPKLERLDS	KTDPASNTKL	IAMKTEKEEM	SFEPGDQPGS	600
ELDNLEEILD	DLQNSQLPQL	FPDTRPGAPA	GSVDKQAIIN	DLMQLTAENS	PVTPVGAQKT	660
ALRISQSTFN	NPRPGQLGRL	LPNQNLPLDI	TLQSPGTAGP	FPIRNSSPY	SVIPQPGMMG	720
NQGMIGNQGN	LGNSSTGMIG	NSASRPTMPS	GEWAPQSSAV	RVTCAATTS	MNRPVQGGMI	780
RNPAASIPMR	PSSQPGQRQT	LQSQVMNIGP	SELEMMMGPP	QYSQQAPPN	QTAPWPESIL	840
PIDQASFAQ	NRQPFSSPD	DLLCPHPAAE	SPSDEGALLD	QLYLALRNFD	GLEEIDRALG	900
IPELVQSQA	VDPEQFSSQD	SNIMLEQKAP	VFPQQYASQA	QMAQGSYSPM	QDPNFHTMGQ	960
RPSYATLRMQ	PRPGLRPTGL	VQNQPNQLRL	QLQHLRLAQQ	NRQPLMNQIS	NVSNVNLTLR	1020
PGVPTQAPIN	AQMLAQQRQ	ILNQHLRQRQ	MHQQQQVQQR	TLMMRQGLN	MTPSMVAPSG	1080
MPATMSNPRI	PQANAQQQFF	PPNYGISQQP	DPGFTGATTP	QSPLMSPRMA	HTQSPMMQOS	1140
QAMPAYQAPS	DINGWAQGNM	GGNSMFSQQS	PPHFGQANT	SMYSNNMNIN	VSMATNTTGM	1200
SSMNQMTGQI	SMTSVTSVPT	SGLSSMGPEQ	VNDPALRGGN	LFPNQLPGMD	MIKQEGDTTR	1260
KYC						1263

D

1	ggcgcccgca	gcctcggtca	cagcttcggc	ggcgaaggtc	agcgccgacg	gcagccggca
61	cctgacggcg	tgaccgaccc	gagccgattt	ctcttggtatt	tggctacaca	cttatagatc
121	ttctgcactg	tttacaggca	cagttgctga	tatgtgttca	agatgagtgg	gatgggagaa
181	aatacacctg	accctccagc	ggcagagaca	agaaagcgca	aggaatgtcc	tgaccaactt
241	ggaccacgcc	ccaaaaggaa	cactgaaaaa	cgtaatcgtg	aacaggaaaa	taaatatata
301	gaagaaactg	cagagtgtat	tttgcaaat	tttaatgata	tagacaactt	taacttcaaa
361	cctgacaaat	gtgcaatctt	aaaagaaact	gtgaagcaaa	ttcgtcagat	caaagaacaa
421	gagaaagcag	cagctgcgca	catagatgaa	gtgcagaagt	cagatgtatc	ctctacaggg
481	cagggtgtca	tcgacaaagg	tcgctggggg	cctatgatgc	ttgaggccct	tgatgggttc
541	ttctttgtag	tgaacctgga	aggcaacgtt	gtgtttgtgt	cagagaatgt	gacacagtat
601	ctaaggatata	accaagaaga	gctgatgaac	aaaagtgtat	atagcatctt	gcatgttggg
661	gaccacacgg	aatttgtcaa	aaacctgctg	ccaaagtcta	taggtaaatg	ggggatcttg
721	gtctggcgaa	cctccgaggg	ggaacagcca	taccttcaat	tgctggatgc	tggtaaaaac
781	tttacctgat	tcagaagagg	agggtcatga	taaccaggaa	gctcatcaga	aatatgaaac
841	tatgcagtgc	ttcgtgtctt	ctcaacccaa	gtccatcaaa	gaagaaggag	aagatttgca
901	gtcctgcttg	atttgcgttg	caagaagagt	tcccatgaag	gaaagaccag	ttcttccctc
961	atcagaagt	tttactactc	gccaggatct	ccaaggcaag	atcacgtctc	tggtataccag
1021	caccatgaga	gcagccatga	aaccaggctg	ggaggacctg	gtaagaaggt	gtattcagaa
1081	gttccatcgc	cagcatgaag	gagaatctgt	gtcctatgct	aagaggcatc	atcatgaagt
1141	actgagacaa	ggattggcat	tcagtcaaat	ctatcggttt	tccttgcctg	atggcactct
1201	tggtgtctga	caaacgaaga	gcaaaactcat	ccgttctcag	actactaatg	aacctcaact
1261	tgtaatatct	ttacatatgc	ttcacagaga	gcagaatgtg	tgtgtgatga	atccggatct
1321	gactggacaa	acgatgggga	agccactgaa	tccaattagc	tctaacagcc	ctgcccatac
1381	ggccctgtgc	agtgggaacc	caggtcagga	catgaccctc	agtagcaata	taaattttcc
1441	cataaatggc	ccaaaggaa	aaatgggcat	gcccatgggc	agggttggtg	gttctggggg
1501	aatgaacat	gtgtcaggga	tgcaagcaac	cactcctcag	ggtagtaact	atgcactcaa
1561	aatgaacagc	ccctcacaaa	gcagccctgg	catgaatcca	ggacagccca	cctccatgct
1621	ttcaccaagg	catcgcatga	gccctggagt	ggctggcagc	cctcgaaatc	cacccagtca
1681	gttttccctc	gcagggaagt	tgcatccccc	tgtgggagtt	tgacgcagca	caggaaatag
1741	ccatagtatt	accaacagct	ccctcaatgc	acttcaggcc	ctcagcgagg	ggcaggggtg
1801	ctcattaggg	tcactgcttg	cttcaccaga	cctaataatg	ggcaatttgc	aaaactcccc
1861	agttaatatg	aatcctcccc	cactcagcaa	gatgggaagc	ttggactcaa	aagactgttt
1921	tggactatat	ggggagccct	ctgaaggtac	aactggacaa	gcagagagca	gctgccatcc
1981	tggagagcaa	aaggaaacaa	atgaccccaa	cctgcccccg	gccgtgagca	gtgagagagc
2041	tgacgggcag	agcagactgc	atgacagcaa	agggcagacc	aaactcctgc	agctgctgac
2101	caccaaattc	gatcagatgg	agccctcgcc	cttagccagc	tctttgtcgg	atacaaacaa
2161	agactccaca	ggtagcttgc	ctggttctgg	gtctacacat	ggaacctcgc	tcaaggagaa
2221	gcataaaatt	ttgcacagac	tcttgtagga	cagcagttcc	cctgtggact	tggccaaagt
2281	aacagcagaa	gccacaggca	aagacctgag	ccaggagtcc	agcagcacag	ctcctggatc
2341	agaagtgtact	attaaacaag	agccggtgag	ccccaaagag	aaagagaatg	cactacttcg
2401	ctatttgcta	gataaagatg	atactaaaga	tattggttta	ccagaaataa	cccccaact
2461	tgagagactg	gacagtgaag	cagatcctgc	cagtaacaca	aaattaatag	caatgaaaac
2521	tgagaaggag	gagatgagct	ttgagcctgg	tgaccagcct	ggcagtgaag	tggacaactt
2581	ggaggagatt	ttggtatgatt	tgacgaatag	tcaattacca	cagcttttcc	cagacacgag
2641	gccagggccc	cctgtcggat	cagttgacaa	gcaagccatc	atcaatgacc	tcatgcaact
2701	cacagctgaa	aacagccctg	tcacacctgt	tggagccccc	aaaacagcac	tgcgaaattc

Fig. 3 D (continued):

```

2761 acagagcact tttataaacc cagcaccagg gcaactgggc aggttattgc caaaccagaa
2821 tttaccactt gacatcacat tgcaaaagccc aactgggtgct ggacctttcc caccaatcag
2881 aaacagtagt cctactcag tgatacctca gccaggaatg atgggtaatc aagggatgat
2941 aggaaaccaa ggaaatttag ggaacagtag cacaggaatg attggtaaca gtgcttctcg
3001 gcctactatg ccatctggag aatgggcacc gcagagtctg gctgtgagag tcacctgtgc
3061 tgctaccacc agtgccatga accggccagt ccaaggaggt atgattcgga acccagcagc
3121 cagcatcccc atgaggccca gcagccagcc tggccaaaga cagacgcttc agtctcaggt
3181 catgaatata gggccatctg aattagagat gaacatgggg ggacctcagt atagccaaca
3241 acaagctcct ccaaatcaga ctgccccatg gcctgaaagc atcctgccta tagaccaggc
3301 gtcttttgcc agccaaaaca ggagccatt tggcagttct ccagatgact tgctatgtcc
3361 acatcctgca gctgagtctc cgagttagta gggagctctc ctggaccagc tgtatctggc
3421 cttgcggaat tttgatggcc tggaggagat tgatagagcc ttagggaatac ccgaactggt
3481 cagccagagc caagcagtag atccagaaca gttctcaagt caggattcca acatcatgct
3541 ggagcagaag gcgcccgttt tcccacagca gtatgcatct caggcacaaa tggcccaggg
3601 tagctattct ccatgcaag atccaaactt tcacaccatg ggacagcggc ctagtattgc
3661 cacactccgt atgcagccca gaccgggccc caggcccacg ggccatagtc agaaccagcc
3721 aaatcaacta agacttcaac ttcagcatcg cctccaagca cagcagaatc gccagccact
3781 tatgaatcaa atcagcaatg tttccaatgt gaacttgact ctgaggcctg gagtaccaac
3841 acaggcacct attaatgcac agatgctggc ccagagacag agggaaatcc tgaaccagca
3901 tcttcgacag agacaaatgc atcagcaaca gcaagttcag caacgaactt tgatgatgag
3961 aggacaaggg ttgaatatga caccagcat ggtggctcct agtggatatg cagcaactat
4021 gagcaaccct cggattcccc aggcgaatgc acagcagttt ccatttcttc caaactacgg
4081 aataagtcag caacctgac caggctttac tggggctacg actccccaga gcccaacttat
4141 gtcacccaga atggcacata cacagagtcc catgatgcaa cagtctcagg ccaacccagc
4201 ctatcaggcc cctccgaca taaatggatg ggccgagggg aacatgggag gaaacagcat
4261 gttttccag cagtcaccac cacactttgg gcagcaagca aacaccagca tgtacagtaa
4321 caacatgaac atcaatgtgt ccatggcagc caacacaggt ggcatgagca gcatgaacca
4381 gatgacagga cagatcagca tgacctcagt gacctccgtg cctacgtcag ggctgtcttc
4441 catgggtccc gagcaggtta atgatcctgc tctgagggga ggcaacctgt tcccaaacca
4501 gctgcttggg atggatatga ttaagcagga gggagacaca acacggaaat attgctgaca
4561 ctgctgaagc cagttgcttc ttcagctgac cgggctcact tgctcaaaac acttccagtc
4621 tggagagctg tgtctatttg tttcaaccca actgacctgc cagccgggtc tgctagagca
4681 gacaggcctg gccctggttc ccagggtggc gtcactcggg ctgtggcagg aggagctgcc
4741 tcttctcttg acagtctgaa gctcgcatcc agacagtgcg tcagtctgtt cactgcattc
4801 acccttagtc aacttagatc tctcctgcaa aagtaaatgt tgacaggcaa atttcatacc
4861 catgtcagat tgaatgtatt taaatgtatg tatttaagga gaacctatgt cttgttctgt
4921 tctgtttcgg ttccagacac tggtttcttg ctttgttttc cctggctaac agtctagtgc
4981 aaaagattaa gattttatct gggggaaaaga aaagaatttt ttaaaaaatt aaactaaaga
5041 tgttttaagc taaagcctga atttgggatg gaagcaggac agacaccgtg gacagcgctg
5101 tattttacaga cacaccagc gcgtgaagac caacaaagtc acagtcgtat ctctagaaaag
5161 ctctaaagac catgtttggaa agagtctcca gttactgaac agatgaaaag gagcctgtga
5221 gagggctgtt aacattagca aatatttttt ccttgttttt tctttgttaa aaccaaactg
5281 gttcacctga atcatgaatt gagaagaaat aattttcatt tctaatttaa gtccctttta
5341 gtttgatcag acagcttgaa tcagatcttc ttcttccctg tcagcctgac tcttcccttc
5401 cctctctcca ttccccatac tccctatttt cattcccttt ttaaaaaata atataagcta
5461 cagaaaccag gtaagccctt tatttcctta aatgttttgc cagccactta ccaattgcta
5521 agtatgtaat ttcagaaaaa aaaaatgcat ttactggcaa ggagaagagc aaagttaagg
5581 cttgatacca atcgagctaa ggatacctgc tttggaagca tgtttattct gttccccagc
5641 aactctggcc tccaaaatgg gagaaaacgc cagtgtgttt aaattgatag cagatatcac
5701 gacagattta acctctgcca tgtgtttttt attttgtttt tttagcagtc tgactaagcc
5761 gaagttttgt aaggtacata aaatccaatt tatatgtaaa caagcaataa ttttaagtga
5821 gaacttatgt gttttaattg tataattttt gtgaggtata catattgtgg aattgactca
5881 aaaaatgaggt acttcagtat taaaatagat atcttcatag caatgtctcc taaagtggtt
5941 ttgtaaaagg tatcaatgcc ttgattagac ctaatttgta gacttaagac tttttatttt
6001 ctaaaccttg tgattctgct tataagtcac ttatctaatc tatatgatat gcagccgctg
6061 taggaaccaa ttcttgattt ttatatgttt atattcttct ttaatgaacc ttagaaaagc
6121 tacatgttac taagcaggcc acttttatgg ttgttttt

```



**Fig. 3 E:**

```

1  MSSPTTSSLD TPLPGNGPPQ PGAPSSSPTV KEEGPEPWPG GPDPDVPGTD EASSACSTDW
61  VIPDPEEEEPE RKRRKGPAPK MLGHELRCRVC GDKASGFHYN VLSCEGCKGF FRRSVVRGGA
121 RRYACRGGGT CQMDAFMRRK CQCRLRKCK EAGMREQCVL SEEQIRKKKI RKQQQESQSQ
181 SQSPVGPQGS SSSASGPGAS PGGSEAGSQG SGEGEVQLT AAQELMIQQL VAAQLQCNKR
241 SFSDQPKVTP WPLGADPQSR DARQORFAHF TELAIISVQE IVDFAKQVPG FLQLGREDQI
301 ALLKASTIEI MLEETARRYN HETECITFLK DFTYSKDDFH RAGLQVEFIN PIPEFSRAMR
361 RLGLDDAEYA LLIAINIFSA DRPNVQEPGR VEALQQPYVE ALLSYTRIKR PQDQLRFPRM
421 LMKLVSLRTL SSVHSEQVFA LRLQDKKLPP LLSEIWDVHE

```






**Fig. 3 F:**

```

1  atgtcctctc ctaccacgag ttccctggat accccctgc ctggaaatgg ccccccctcag
61  cctggcgccc cttcttcttc acccactgta aaggaggagg gtccggagcc gtggcccggg
121 ggtccggacc ctgatgtccc aggcactgat gaggccagct cagcctgcag cacagactgg
181 gtcatcccag atcccgaaga ggaaccagag cgcaagcgaa agaaggggccc agccccgaag
241 atgctggggc acgagctttg ccgtgtctgt ggggacaagg cctccggcct ccactacaac
301 gtgctcagct gcgaaggctg caagggtctt ttccggcgca gtgtggtccg tgggtggggcc
361 aggcgctatg cctgccgggg tggcggaacc tgccagatgg acgctttcat gcggcgcaag
421 tgccagcagt gccggctgcg caagtgcag gaggcaggga tgaggagca gtgcgtcctt
481 tctgaagaac agatccggaa gaagaagatt cggaaacagc agcaggagtc acagtccag
541 tcgcagtcac ctgtggggcc gcagggcagc agcagctcag cctctggggc tggggcttcc
601 cctggtggat ctgaggcagg cagccagggc tccggggaag gcgagggtgt ccagctaaca
661 gcggctcaag aactaatgat ccagcagttg gtggcgggcc aactgcagtg caacaaacgc
721 tccttctccg accagcccaa agtcacgccc tggcccctgg gcgcagacct ccagtcccga
781 gatgcccgcc agcaacgctt tgcccacttc acggagctgg ccatcatctc agtccaggag
841 atcgtggact tcgctaagca agtgccctgt ttcttcgagc tgggcccggg ggaccagatc
901 gccctcctga aggcattccac tatcgagatc atgctgctag agacagccag gcgctacaac
961 cagcagacag agtgtatcac cttcttgaag gacttcacct acagcaagga cgacttccac
1021 cgtgcaggcc tgcaggtgga gttcatcaac cccatcttcg agttctcgcg ggccatgcgg
1081 cggtcgggcc tggacgacgc tgagtacgcc ctgctcatcg ccatcaacat cttctcggcc
1141 gaccggccca acgtgcagga gccgggcccgc gtggaggcgt tgcagcagcc ctacgtggag
1201 gcgctgctgt cctacacgcg catcaagagg ccgcaggacc agctgcgctt cccgcgcatg
1261 ctcataaagc tgggtgagcct gcgcacgctg agctctgtgc actcggagca ggtctctgcc
1321 ttgcggctcc aggacaagaa gctgccgcct ctgctgtcgg agatctggga cgtccacgag
1381 tga

```

Fig. 4 A:

MOLNAME	MOLECULE STRUCTURE	EC50 AVG	EFFIC AVG
LN0000003252		0.59	110
LN0000007459		0.12	129
LN0000011283		0.18	137
TR1040007465		1.2	114
LN0000007460		2,6	111
LN0000006500		0,34	133



			
LN0000006494		0,23	112

Fig. 4 A (cont.)






MOLNAME	MOLECULE STRUCTURE	EC50 AVG	EFFIC AVG
LN0000007364		1.5	101
LN0000003492		0.11	115
LN0000007180		0.15	128
LN0000007179		0.78	127

Fig. 4 A (cont.):

Fig. 5:



**Fig. 6**

Liver X receptor alpha, LXR $\alpha$  (NM\_005693)  
 Cholesterol 7  $\alpha$  hydroxylase, Cyp7A1 (NM\_000780)  
 FAS (NM\_004104)  
 Stearyl CoA desaturase, SCD (XM\_030447)  
 Sterol Response Element Binding Protein 1C, SREBP-1C (NM\_004176)  
 ATP binding cassette transporter A1; ABCA1 (NM\_005502)  
 ATP binding cassette transporter G1; ABCG1 (XM\_032950)  
 ATP binding cassette transporter A1; ABCG5 (NM\_031884)  
 ATP binding cassette transporter A1; ABCG8 AF324494  
 Apolipoprotein E, apoE (NM\_000041)  
 Apolipoprotein C-I, apoC-I (NM\_001645)  
 Apolipoprotein C-II apoC-II (NM\_000483)  
 Apolipoprotein C-IV, apoC-IV (U32576)  
 Lipoprotein Lipase, LPL (M15856)  
 Cholesteryl Ester Transfer Protein, CETP (NM\_000078)

Fig. 7:




Fig. 8A:






Fig. 8B




Fig. 9





Fig. 10:





European Patent  
Office

# PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent Convention EP 02 02 0255 shall be considered, for the purposes of subsequent proceedings, as the European search report

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	WO 02 062798 A (REDDY RESEARCH FOUNDATION) 15 August 2002 (2002-08-15) * claim 1 * * page 106, line 22 - page 107, line 6 * * page 1, line 17 - page 2, line 16 * ---	1,13-33	A61K31/517 C07D239/95 C07D401/12 C07D403/04 A61P3/06
X	WO 97 20823 A (CRISCIONE LEOLUCA ;YAMAGUCHI YASUCHIKA (CH); CIBA GEIGY AG (CH); M) 12 June 1997 (1997-06-12) * page 74; example 38 * * page 1, paragraph 1 * ---	1,13,18, 22,30, 32,35	
X	WO 02 48152 A (BAKTHAVATCHALAM RAJAGOPAL ;BRIELMANN HARRY L (US); ELLIOTT RICHARD) 20 June 2002 (2002-06-20) * page 59; example 12 * * page 6, paragraph 17 * ---	1,13,18, 22,30, 32,35	
-/--			
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
			C07D A61K A61P
<b>INCOMPLETE SEARCH</b>			
<p>The Search Division considers that the present application, or one or more of its claims, does/do not comply with the EPC to such an extent that a meaningful search into the state of the art cannot be carried out, or can only be carried out partially, for these claims.</p> <p>Claims searched completely :</p> <p>Claims searched incompletely :</p> <p>Claims not searched :</p> <p>Reason for the limitation of the search:</p> <p>see sheet C</p>			
Place of search		Date of completion of the search	Examiner
MUNICH		18 December 2002	Kollmannsberger, M
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons ..... &amp; : member of the same patent family, corresponding document</p>			

EPO FORM 1503 03.82 (P04C07)



European Patent  
Office

INCOMPLETE SEARCH  
SHEET C

Application Number

EP 02 02 0255

Claims 14-25, 34, 35 are directed to a method of treatment of the human/animal body (Article 52(4) EPC). Insofar as the claims could be searched, the search has been carried out based on the alleged effects of the compounds.

-----

Claim(s) searched completely:

4-10

Claim(s) searched incompletely:

1-3, 11-35

Reason for the limitation of the search:

Claims 1-12 encompass a large number of known compounds. The initial phase of the search revealed a very large number of documents relevant to the issue of novelty. So many documents were retrieved that it is impossible to determine which parts of the claim(s) may be said to define subject-matter for which protection might legitimately be sought (Article 84 EPC). Additionally, support within the meaning of Article 84 EPC and disclosure within the meaning of Article 83 EPC is to be found, for only a very small proportion of the compounds and methods claimed. For these reasons, a meaningful search over the whole breadth of the claims is impossible. Consequently, the search is only complete for:

Compounds according to claims 4-10 which are mentioned in the prior art to have useful properties in the treatment of the diseases mentioned in claims 29-32; compounds as such according to claims 4-10.

Only some documents relevant to other subject-matter of the claims have been cited for illustration.



European Patent  
Office

## PARTIAL EUROPEAN SEARCH REPORT

Application Number  
EP 02 02 0255

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
D,A	COLLINS, J. L. ET AL.: "Identification of a Nonsteroidal Liver X Receptor Agonist through Parallel Array Synthesis of Tertiary Amines" JOURNAL OF MEDICINAL CHEMISTRY, vol. 45, 2002, pages 1963-1966, XP002225147 * the whole document *	1-33	
X	GUPTA C M ET AL: "Drugs acting on the central nervous system. Syntheses of substituted quinazolones and quinazolines and triazepino- and triazocinoquinazolones" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, US, vol. 11, no. 2, 26 February 1968 (1968-02-26), pages 392-395, XP002156695 ISSN: 0022-2623 * examples 13-16,22,23,38; table 2 *	1,4,8,13	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
X	MANABU HORI ET AL: "Novel 4-Substituted 2-Piperazinyquinazolines as potent Anticonvulsive and Antihypoxic Agents" CHEMICAL AND PHARMACEUTICAL BULLETIN, PHARMACEUTICAL SOCIETY OF JAPAN, TOKYO, JP, vol. 38, no. 5, 1990, pages 1286-1291, XP002128282 ISSN: 0009-2363 * examples 3A-3H; table II *	1	
X	US 3 609 152 A (HESS HANS-JURGEN E ET AL) 28 September 1971 (1971-09-28) * examples III-X *	1,4,8,13	
	---		
	-/--		



European Patent  
Office

## PARTIAL EUROPEAN SEARCH REPORT

Application Number  
EP 02 02 0255

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
X	<p>DATABASE CHEMCATS [Online]            CHEMICAL ABSTRACTS SERVICE, COLUMBUS,            OHIO, US;            XP002225148            Order Number: TRG10400#07364-D;            TRG10400#01891-D; TRG10400#01815-D;            TRG10400#01814-D; TRG10400#01812-D;            TRG10400#01811-D; TRG10400#01809-D;            TRG10400#01736-D; TRG10400#01735-D;            TRG10400#01732-D;            TRG10400#01729-D            &amp; "Chem.Folio"            15 January 2001 (2001-01-15) , LION            BIOSCIENCE AG , HEIDELBERG, GERMANY            -----</p>	1-3,9	<div>TECHNICAL FIELDS SEARCHED (Int.Cl.7)</div>

**ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.**

EP 02 02 0255

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.  
The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

18-12-2002

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 02062798 A	15-08-2002	WO 02062798 A2	15-08-2002
		WO 02062799 A1	15-08-2002
		US 2002169175 A1	14-11-2002
-----			
WO 9720823 A	12-06-1997	AU 7692996 A	27-06-1997
		WO 9720823 A2	12-06-1997
		ZA 9610020 A	01-06-1997
-----			
WO 0248152 A	20-06-2002	AU 2027602 A	24-06-2002
		WO 0248152 A2	20-06-2002
-----			
US 3609152 A	28-09-1971	BE 678216 A	22-09-1966
		DE 1620127 A1	12-03-1970
		FR 5267 M	31-07-1967
		GB 1062357 A	22-03-1967
		GB 1174272 A	17-12-1969
		GB 1174273 A	17-12-1969
-----			

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82